

10/560,887

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600txm

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 21:04:29 ON 16 MAR 2010
FILE 'REGISTRY' ENTERED AT 21:04:29 ON 16 MAR 2010
COPYRIGHT (C) 2010 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.84	604.76
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-56.10

=> d his

(FILE 'HOME' ENTERED AT 20:18:02 ON 16 MAR 2010)

FILE 'REGISTRY' ENTERED AT 20:18:28 ON 16 MAR 2010
L1 STRUCTURE uploaded
L2 29 S L1
L3 504 S L1 FULL

FILE 'REGISTRY' ENTERED AT 20:20:52 ON 16 MAR 2010

FILE 'CAPLUS' ENTERED AT 20:21:01 ON 16 MAR 2010
L4 66 S L3

FILE 'REGISTRY' ENTERED AT 20:29:36 ON 16 MAR 2010

FILE 'REGISTRY' ENTERED AT 20:44:55 ON 16 MAR 2010

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	9.31	606.23
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-56.10

FILE 'CAPLUS' ENTERED AT 21:06:25 ON 16 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Mar 2010 VOL 152 ISS 12
FILE LAST UPDATED: 15 Mar 2010 (20100315/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

CAplus now includes complete International Patent Classification (IPC)

McIntosh

reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>



This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitstr 1-66 14

L4 ANSWER 1 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2010:85102 CAPLUS
 DN 152:144974
 TI Preparation of nucleoside phosphoramidate prodrugs as antiviral agents
 IN Sofia, Michael Joseph; Du, Jinfa; Wang, Peiyuan; Nagarathnam, Dhanapalan
 PA Pharmasset, Inc., USA
 SO U.S. Pat. Appl. Publ., 77pp.; Chemical Indexing Equivalent to 149:426212
 (WO)
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20100016251	A1	20100121	US 2008-53015	20080321
	AU 2008232827	A1	20081009	AU 2008-232827	20080326
	CA 2682230	A1	20081009	CA 2008-2682230	20080326
	WO 2008121634	A2	20081009	WO 2008-US58183	20080326
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	KR 2010016041	A	20100212	KR 2009-722652	20080326
	MX 2009010401	A	20091110	MX 2009-10401	20090928
PRAI	US 2007-909315P	P	20070330		
	US 2007-982309P	P	20071024		
	US 2008-53015	A	20080321		
	WO 2008-US58183	W	20080326		

GI



AB Disclosed herein are nucleoside phosphoramidates prodrugs I, wherein R and

R3 are independently H, alkyl, cycloalkyl, alkylamine, hydroxyalkyl, CH₂SH, alkyl-sulfonyl, (CH₂)₃NHC(=NH)NH₂, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, acyl, aryl, aryl-alkyl; R3 and R both are alkyl; R3 and R together are alkylidene so as to form a spiro ring; R3 is H and R and R2 together are (CH₂)_n so as to form a cyclic ring that includes the adjoining N and C atoms; R is H and R3 and R2 together are (CH₂)_n. so as to form a cyclic ring; that includes the adjoining N and C atoms, n is 2 to 4; one of R and R3 is H and the other is R3 CH₃, Et, CH(CH₃)₂, CH₂CH(CH₃)₂, CH(CH₃)CH₂CH₃, CH₂Ph, CH₂-indol-3-yl, -CH₂CH₂SCH₃, CH₂CO₂H, CH₂C(O)NH₂, CH₂CH₂COOH, CH₂CH₂C(O)NH₂, CH₂CH₂CH₂NH₂, -CH₂CH₂CH₂NHC(NH)NH₂, CH₂-imidazol-4-yl, CH₂OH, CH(OH)CH₃, CH₂((4'-OH)-Ph), CH₂SH, cycloalkyl; R1 is H, alkyl, cycloalkyl, aryl; R2 is H, alkyl; R, R2 and R3 together are (CH₂)_n; R4 is H, alkyl, alkoxy, alkylamino, halo, halo-alkyl, cycloalkyl, aminoacyl, aryl, heterocycle; R5 is H, alkyl, CN, vinyl, hydroxy-alkyl, CH₂OH, CH₂F, CH₂CN, CH₂NH₂, CH₂NHMe, CH₂NMe₂, alkyne; R6 is H, Me, CH₂F, CHF₂, CF₃, F, CN; X is H, OH, F, OMe, halogen, NH₂, N₃; Y is OH, H, alkyl, alkenyl, alkynyl, vinyl, N₃, CN, halo, oxycarbonyl sulfonyl, were prepared and tested as antiviral agents. Thus, nucleoside II was prepared and tested as antiviral agent for the treatment of any condition the result of an infection by hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus or Japanese encephalitis virus.

IT	1015255-46-5P	1064684-23-6P	1064684-24-7P
	1064684-25-8P	1064684-28-1P	1064684-29-2P
	1064684-30-5P	1064684-32-7P	1064684-33-8P
	1064684-36-1P	1064684-37-2P	1064684-38-3P
	1064684-41-8P	1064684-42-9P	1064684-43-0P
	1064684-44-1P	1064684-45-2P	1064684-46-3P
	1064684-47-4P	1064684-48-5P	1064684-49-6P
	1064684-50-9P	1064684-52-1P	1064684-53-2P
	1064684-54-3P	1064684-55-4P	1064684-56-5P
	1064684-57-6P	1064684-58-7P	1064684-59-8P
	1064684-60-1P	1064684-61-2P	1064684-62-3P
	1064684-63-4P	1064684-64-5P	1064684-66-7P
	1064684-67-8P	1064684-68-9P	1064684-69-0P
	1064684-70-3P	1064684-71-4P	1064684-72-5P
	1064684-73-6P	1064684-74-7P	1064684-75-8P
	1064684-76-9P	1064684-77-0P	1064684-78-1P
	1064684-79-2P	1064684-80-5P	1064684-81-6P
	1064684-82-7P	1064684-85-0P	1064684-88-3P
	1064684-92-9P	1064685-44-4P	1064685-46-6P
	1064685-47-7P		


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nucleoside phosphoramidate prodrugs as antiviral agents)

RN 1015255-46-5 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-23-6 CAPLUS


CN L-Valine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-24-7 CAPLUS
 CN L-Valine, N-[(2'R)-P-(4-bromophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-25-8 CAPLUS
 CN L-Alanine, N-[(2'R)-P-(4-bromophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1064684-28-1 CAPLUS
 CN L-Valine, N-[(2'R)-P-(4-bromophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-cytidylyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-29-2 CAPLUS
 CN L-Valine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-cytidylyl]-,

methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-30-5 CAPLUS

CN L-Alanine, N-[2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-32-7 CAPLUS

CN Glycine, N-[2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-33-8 CAPLUS

CN L-Alanine, N-[2'R)-2'-deoxy-P-(2,4-dichlorophenyl)-2'-fluoro-2'-methyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-36-1 CAPLUS


CN L-Alanine, N-[2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, butyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-37-2 CAPLUS
CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-38-3 CAPLUS
CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-P-(4-fluorophenyl)-2'-methyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-41-8 CAPLUS
CN L-Alanine, N-[(2'R)-P-(4-chlorophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1064684-42-9 CAPLUS
CN L-Alanine, N-[(2'R)-2'-deoxy-P-(3,4-dichlorophenyl)-2'-fluoro-2'-methyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-43-0 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 1-methylpropyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-44-1 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-45-2 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-(4-methoxyphenyl)-5'-uridylyl]-, butyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-46-3 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-(4-fluorophenyl)-5'-

uridylyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-47-4 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-P-(4-fluorophenyl)-2'-methyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-48-5 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-P-(4-fluorophenyl)-2'-methyl-5'-uridylyl]-, phenylmethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-49-6 CAPLUS


CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-P-(4-methoxyphenyl)-2'-methyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-50-9 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-52-1 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-P-(2,4-dichlorophenyl)-2'-fluoro-2'-methyl-5'-uridyl]-, butyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1064684-53-2 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-(4-methylphenyl)-5'-uridyl]-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



10/560, 887


RN 1064684-54-3 CAPLUS
CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-P-(4-fluorophenyl)-2'-methyl-5'-uridylyl]-, butyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-55-4 CAPLUS
CN L-Alanine, N-[(2'R)-2'-deoxy-P-(3,4-dichlorophenyl)-2'-fluoro-2'-methyl-5'-uridylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-56-5 CAPLUS
CN L-Alanine, N-[(2'R)-P-(2-chlorophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-57-6 CAPLUS
CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-P-(4-methoxyphenyl)-2'-methyl-5'-uridylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-58-7 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, pentyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-59-8 CAPLUS
 CN L-Alanine, N-[P(R), 2'R]-P-(4-chlorophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1064684-60-1 CAPLUS
 CN L-Alanine, N-[(2'R)-P-(4-chlorophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, butyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-61-2 CAPLUS
 CN L-Alanine, N-[(2'R)-P-(4-chlorophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-

uridylyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-62-3 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-(4-methylphenyl)-5'-uridylyl]-, butyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-63-4 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-(4-methylphenyl)-5'-uridylyl]-, phenylmethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-64-5 CAPLUS


CN Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, 5'-[phenyl N-[(1S)-1-(methoxycarbonyl)propyl]phosphoramide], (2'R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-66-7 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, (4-fluorophenyl)methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-67-8 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 3-methylbutyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-68-9 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-P-(3,4-dichlorophenyl)-2'-fluoro-2'-methyl-5'-uridylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-69-0 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, cyclohexyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-70-3 CAPLUS
 CN D-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-,
 butyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-71-4 CAPLUS
 CN D-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-,
 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-72-5 CAPLUS
 CN D-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-,
 phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-73-6 CAPLUS
 CN L-Alanine, N-[(2'R)-P-(2-chlorophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, butyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-74-7 CAPLUS
 CN L-Alanine, N-[({2'R,3'R}-dR)-P-(4-bromophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-75-8 CAPLUS
 CN L-Alanine, N-[({2'R,3'R}-dR)-P-(4-fluorophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, cyclohexyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-76-9 CAPLUS
 CN L-Alanine, N-[({2'R,3'R}-dR)-P-(4-bromophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, cyclohexyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-77-0 CAPLUS
 CN Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, 5'-(phenyl N-[(1S)-1-[(1-methylethoxy)carbonyl]propyl]phosphoramidate], (2'R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-78-1 CAPLUS
 CN Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, 5'-(phenyl N-[(1S)-1-[(cyclohexyloxy)carbonyl]propyl]phosphoramidate], (2'R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-79-2 CAPLUS
 CN Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, 5'-(4-fluorophenyl N-[(1S)-1-[(cyclohexyloxy)carbonyl]propyl]phosphoramidate], (2'R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-80-5 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 2-fluoroethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-81-6 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 2,2-difluoroethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-82-7 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-85-0 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 2-fluoro-1-(fluoromethyl)ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-88-3 CAPLUS
 CN L-Alanine, N-[({2'R}-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl)-cyclopropylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-92-9 CAPLUS
 CN Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, 5'-(phenyl N-[(1S)-1-[(cyclopentyloxy carbonyl)propyl]phosphoramidate], (2'R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1064685-44-4 CAPLUS
 CN Glycine, N-[{P(S),2'R}-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064685-46-6 CAPLUS
 CN L-Alanine, N-[{P(S),2'R}-P-(4-chlorophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064685-47-7 CAPLUS
 CN L-Alanine, N-[(P(S)(S)-2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, cyclohexyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 1064684-27-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of nucleoside phosphoramidate prodrugs as antiviral agents)
 RN 1064684-27-0 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-cytidylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:1507900 CAPLUS
 DN 152:183433
 TI Anti-hepatitis C virus activity of novel β -d-2'-C-methyl-4'-azido pyrimidine nucleoside phosphoramidate prodrugs
 AU Rondla, Ramu; Coats, Steven J.; McBrayer, Tamara R.; Grier, Jason; Johns, Melissa; Tharnish, Phillip M.; Whitaker, Tony; Zhou, Longhu; Schinazi, Raymond F.
 CS Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Veterans Affairs Medical Center, Atlanta, GA, USA
 SO Antiviral Chemistry & Chemotherapy (2009), 20(2), 99-106
 CODEN: ACCHEH; ISSN: 0956-3202
 URL: <http://www.intmedpress.com/journals/avcc/abstract.cfm?id=1400&pid=108>
 PB International Medical Press, Ltd.
 DT Journal; (online computer file)
 LA English
 AB Background: 2'-C-Me and 4'-azido nucleosides have previously demonstrated

inhibition of hepatitis C virus (HCV) replication by targeting the RNA-dependent RNA polymerase NS5B. In an effort to discover new and more potent anti-HCV agents, we envisioned synthesizing nucleoside analogs by combining the 2'-C-methyl-moiety with the 4'-azido-moiety into one mol. Methods: 2'-C-methyl-4'-azido pyrimidine nucleosides were synthesized by first converting 2'-C-Me ribo-nucleosides to the corresponding 4'-exocyclic methylene nucleosides. Treatment with iodine azide, benzylation of the 2'- and 3'-hydroxy groups, oxidative displacement of the 5'-iodo group with p-chloroperoxybenzoic acid, and debenzylation gave the desired 2'-C-methyl-4'-azido uridine and thymidine analogs in good yield. Standard conversion of uridine to cytidine via the 4-triazole yielded 2'-C-methyl-4'-azido cytidine. In addition, 5'-phosphoramidate derivs. of 2'-C-methyl-4'-azido uridine and cytidine were synthesized to bypass the initial phosphorylation step. Results: The prepared nucleosides and their 5'-monophosphate prodrugs were evaluated for their ability to inhibit replication of the hepatitis C virus in a sub-genomic replicon cell based assay. Cytotoxicity in Huh7 cells was determined simultaneously with anti-HCV activity by extraction and amplification of both HCV RNA and rRNA. Among the newly synthesized compds., only the 5'-monophosphate nucleoside prodrugs had modest and selective anti-HCV activity. All prepared pyrimidine nucleosides and 5'-monophosphate nucleoside prodrugs displayed no evidence of cytotoxicity at high concns. Conclusions: This work is the first example of both inactive uridine and cytidine analogs of a nucleoside being converted to active anti-HCV nucleosides via 5'-monophosphate prodrugs.


IT 1206126-51-3P 1206126-54-6P

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (anti-hepatitis C virus activity of novel methylazido pyrimidine nucleosides phosphoramidate prodrugs)

RN 1206126-51-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1206126-54-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:952853 CAPLUS


DN 151:313498

TI Phosphoramidate Prodrugs of 2'-C-Methylcytidine for Therapy of Hepatitis C Virus Infection

AU Gardelli, Cristina; Attenni, Barbara; Donghi, Monica; Meppen, Malte;
 Pacini, Barbara; Harper, Steven; Di Marco, Annalise; Fiore, Fabrizio;


Giuliano, Claudio; Pucci, Vincenzo; Laufer, Ralph; Gennari, Nadia;
 Marcucci, Isabella; Leone, Joseph F.; Olsen, David B.; MacCoss, Malcolm;
 Rowley, Michael; Narjes, Frank
 CS Departments of Medicinal Chemistry and Pharmacology, Istituto di Ricerche
 di Biologia Molecolare, P. Angeletti S.p.A. (IRBM-MRL Rome), Pomezia,
 00040, Italy
 SO Journal of Medicinal Chemistry (2009), 52(17), 5394-5407
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 151:313498
 AB The application of a phosphoramidate prodrug approach to
 2'-C-methylcytidine (NM107), the first nucleoside inhibitor of the
 hepatitis C virus (HCV) NS5B polymerase, is reported.
 2'-C-Methylcytidine, as its valyl ester prodrug (NM283), was efficacious
 in reducing the viral load in patients infected with HCV. Several of the
 phosphoramidates prepared demonstrated a 10- to 200-fold superior potency
 with respect to the parent nucleoside in the cell-based replicon assay.
 This is due to higher levels of 2'-C-methylcytidine triphosphate in the
 cells. These prodrugs are efficiently activated and converted to the
 triphosphate in hepatocytes of several species. Our SAR studies
 ultimately led to compds. that gave high levels of NTP in hamster and rat
 liver after s.c. dosing and that were devoid of the toxic phenol moiety
 usually found in ProTides.
 IT 946511-07-5P 946511-13-3P 946511-29-1P
 946511-32-6P 946511-37-1P 946511-45-1P
 946511-46-2P 946511-59-7P 946511-63-3P
 946511-68-8P 946511-72-4P 946511-74-6P
 946511-76-8P 946511-78-0P 946511-81-5P
 946511-82-6P 1035638-04-0P 1035638-21-1P
 1185923-61-8P 1185923-63-0P 1185923-73-2P
 1185923-76-5P 1185923-79-8P 1185923-81-2P
 1185923-83-4P 1185923-88-9P 1185923-90-3P
 1185923-92-5P 1185923-94-7P 1185923-96-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation and antihepatitis activity of methylcytidine phosphoramidate
 prodrugs via condensation of methylcytidine with
 aryloxyphosphorochloridates)
 RN 946511-07-5 CAPLUS
 CN L-Alanine, N-(2'-C-methyl-P-1-naphthalenyl-5'-cytidylyl)-, ethyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-13-3 CAPLUS
 CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, ethyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-29-1 CAPLUS
 CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-32-6 CAPLUS
 CN L-Alanine, N-[2'-C-methyl-P-[4-(trifluoromethyl)phenyl]-5'-cytidylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 946511-37-1 CAPLUS
 CN L-Alanine, N-[P-(4-methoxyphenyl)-2'-C-methyl-5'-cytidylyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-45-1 CAPLUS
 CN L-Alanine, N-[P-(2-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, butyl ester

(CA INDEX NAME)


Absolute stereochemistry.



RN 946511-46-2 CAPLUS

CN L-Alanine, N-[P-(4-chloro-1-naphthalenyl)-2'-C-methyl-5'-cytidylyl]-, butyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-59-7 CAPLUS

CN L-Alanine, N-[2'-C-methyl-P-(2-methylphenyl)-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-63-3 CAPLUS


CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-68-8 CAPLUS
 CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, propyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-72-4 CAPLUS
 CN L-Leucine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-74-6 CAPLUS
 CN L-Norleucine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-76-8 CAPLUS
 CN Glycine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-78-0 CAPLUS
 CN Cytidine, 2'-C-methyl-, 5'-[4-chlorophenyl]
 N-[(1S)-2-ethoxy-2-oxo-1-phenylethyl]phosphoramidate] (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-81-5 CAPLUS
 CN L-Tryptophan, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 946511-82-6 CAPLUS
 CN L-Alanine, N-[P-[2-(methoxycarbonyl)phenyl]-2'-C-methyl-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



10/560, 887


RN 1035638-04-0 CAPLUS
CN L-Alanine, N-[P(R)]-P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1035638-21-1 CAPLUS
CN L-Alanine, N-[P(S)]-P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1185923-61-8 CAPLUS
CN D-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1185923-63-0 CAPLUS
CN L-Phenylalanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1185923-73-2 CAPLUS
 CN L-Alanine, N-(2'-C-methyl-P-1-naphthalenyl-5'-cytidylyl)-, butyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 1185923-76-5 CAPLUS
 CN L-Alanine, N-[P-[4-chloro-5-methyl-2-(1-methylethyl)phenyl]-2'-C-methyl-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1185923-79-8 CAPLUS
 CN L-Alanine, N-[2'-C-methyl-P-[2-(2,2,2-trichloroethyl)phenyl]-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1185923-81-2 CAPLUS
 CN L-Tyrosine, O-[P-deoxy-P-[(1S)-2-ethoxy-1-methyl-2-oxoethyl]amino]-2'-C-methyl-5'-cytidylyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1185923-83-4 CAPLUS
 CN L-Alanine, N-[P-[1-[1,1-dimethylethoxy carbonyl]-1H-indol-5-yl]-2'-C-methyl-5'-cytidylyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1185923-88-9 CAPLUS
 CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, 3-methoxypropyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1185923-90-3 CAPLUS
 CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, 1-ethylbutyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1185923-92-5 CAPLUS
 CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, heptyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1185923-94-7 CAPLUS
 CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, cycloheptyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1185923-96-9 CAPLUS
 CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, 1-propylpentyl ester (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L4 ANSWER 4 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:875224 CAPLUS
 DN 151:381628
 TI Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine
 AU Meppen, Malte; Pacini, Barbara; Bazzo, Renzo; Koch, Uwe; Leone, Joseph F.; Koepplinger, Kenneth A.; Rowley, Michael; Altamura, Sergio; Di Marco, Annalise; Fiore, Fabrizio; Giuliano, Claudio; Gonzalez-Paz, Odalys; Laufer, Ralph; Pucci, Vincenzo; Narjes, Frank; Gardelli, Cristina
 CS Department of Chemistry - Istituto di Ricerche di Biologia Molecolare, P. Angeletti S.p.A., Pomezia, 00040, Italy
 SO European Journal of Medicinal Chemistry (2009), 44(9), 3765-3770
 CODEN: EJMCA5; ISSN: 0223-5234
 PB Elsevier Masson SAS
 DT Journal
 LA English
 AB The currently approved treatment for hepatitis C virus infections is a combination of Ribavirin and pegylated Interferon. It leads to a

sustained virol. response in approx. only half of the patients treated. For this reason there is an urgent need of new therapeutic agents. 2'-C-Methylcytidine is the first nucleoside inhibitor of the HCV NS5B polymerase that was efficacious in reducing the viral load in patients infected with HCV. The application of a monophosphate prodrug approach based on unprecedented cyclic phosphoramidates is reported. The SAR studies led to compds. that are efficiently converted to the active triphosphate in human hepatocytes.


IT 1035638-04-0P 1035638-21-1P

RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(asym. synthesis and antiviral activity of methylcytidine cyclic phosphoramidates as prodrugs via coupling of phosphoramidate chlorides with methylcytidine, and intramol. cyclization of phosphoramidates)

RN 1035638-04-0 CAPLUS

CN L-Alanine, N-[[P(R)]-P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1035638-21-1 CAPLUS

CN L-Alanine, N-[[P(S)]-P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2009:845570 CAPLUS

DN 151:328021

TI The application of phosphoramidate ProTide technology to the potent anti-HCV compound 4'-azidocytidine (R1479)

AU McGuigan, Christopher; Kelleher, Mary Rose; Perrone, Plinio; Mulready, Sinead; Luoni, Giovanna; Daverio, Felice; Rajaguru, Sonal; Le Pogam, Sophie; Najera, Isabel; Martin, Joseph A.; Klumpp, Klaus; Smith, David B.

CS Welsh School of Pharmacy, Cardiff University, Cardiff, CF10 3NB, UK

SO Bioorganic & Medicinal Chemistry Letters (2009), 19(15), 4250-4254
CODEN: BMCL8; ISSN: 0960-894X

PB Elsevier B.V.

DT Journal

LA English

OS CASREACT 151:328021

AB The design, synthesis and evaluation of a family of ca. 50 phosphoramidate ProTides of the potent anti-HCV (hepatitis C virus) compound 4'-azidocytidine (R1479), with variation on the ester, amino acid and aryl moiety of the ProTide, are reported. Sub-micromolar inhibitors of HCV emerge. The compds. are all non-cytotoxic in the replicon assay. Herein are reported detailed SARs for each of the regions of the ProTide.


IT 926308-35-2P 926308-39-6P 926308-40-9P
 926308-42-1P 926308-49-8P 926308-56-7P
 926308-58-9P 926308-59-0P 926308-61-4P
 926308-67-0P 926308-79-4P 926308-88-5P
 926308-91-0P 926308-95-4P 926308-98-7P
 926309-01-5P 926309-03-7P 926309-05-9P
 926309-18-4P 926309-22-0P 926309-24-2P
 926309-29-7P 926309-35-5P 926309-42-4P
 926309-45-7P 926309-46-8P 926309-64-0P
 926309-67-3P 926309-76-4P 926309-85-5P
 1186412-19-0P 1186412-22-5P 1186412-23-6P
 1186412-24-7P 1186412-25-8P 1186412-26-9P
 1186412-28-1P 1186412-29-2P 1186412-30-5P
 1186412-31-6P 1186412-32-7P 1186412-33-8P
 1186412-34-9P 1186412-35-0P 1186412-37-2P
 1186412-38-3P 1186412-39-4P 1186412-40-7P
 1186412-41-8P 1186412-42-9P 1186412-43-0P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (application of phosphoramidate ProTide technol. to the potent anti-hepatitis C virus compound 4'-azidocytidine (R1479) to produce new antiviral agents)

RN 926308-35-2 CAPLUS

CN L-Phenylalanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 926308-39-6 CAPLUS

CN L-Phenylalanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 926308-40-9 CAPLUS


CN L-Phenylalanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-42-1 CAPLUS
 CN Cytidine, 4'-C-azido-, 5'-(phenyl N-[1,1-dimethyl-2-oxo-2-phenylmethoxy)ethyl]phosphoramidate] (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-49-8 CAPLUS
 CN Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-2-methyl-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-56-7 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, 1-methylpropyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-58-9 CAPLUS
 CN D-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-59-0 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-61-4 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-67-0 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-79-4 CAPLUS
 CN Cytidine, 4'-C-azido-, 5'-[phenyl N-[1-(ethoxycarbonyl)cyclopentyl]phosphoramidate] (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-88-5 CAPLUS
 CN L-Leucine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-91-0 CAPLUS
 CN L-Leucine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-95-4 CAPLUS
 CN L-Leucine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-98-7 CAPLUS
 CN L-Valine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-01-5 CAPLUS
 CN L-Isoleucine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-03-7 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-05-9 CAPLUS
 CN D-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-18-4 CAPLUS
 CN D-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, dodecyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-22-0 CAPLUS
 CN L-Methionine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-24-2 CAPLUS
 CN L-Glutamic acid, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, 1,5-diethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-29-7 CAPLUS
 CN L-Leucine, N-[4'-C-azido-P-(4-chlorophenyl)-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-35-5 CAPLUS
 CN L-Leucine, N-[4'-C-azido-P-(3,4-dichlorophenyl)-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-42-4 CAPLUS
 CN L-Leucine, N-[4'-C-azido-P-(4-methylphenyl)-5'-cytidylyl]-, ethyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-45-7 CAPLUS
 CN L-Leucine, N-[4'-C-azido-P-(4-methoxyphenyl)-5'-cytidylyl]-, ethyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-46-8 CAPLUS
 CN L-Alanine, N-[4'-C-azido-P-(4-methoxyphenyl)-5'-cytidylyl]-, phenylmethyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-64-0 CAPLUS
 CN L-Aspartic acid, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, 1,4-diethyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-67-3 CAPLUS
 CN D-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, 1,1-dimethylethyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-76-4 CAPLUS
 CN D-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, butyl ester (CA INDEX
 NAME)

Absolute stereochemistry.




RN 926309-85-5 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, 1-methylethyl ester (CA
 INDEX NAME)

Absolute stereochemistry.




RN 1186412-19-0 CAPLUS
 CN Glycine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, phenylmethyl ester (CA
 INDEX NAME)

Absolute stereochemistry.




RN 1186412-22-5 CAPLUS
 CN Glycine, N-[P(R)]-4'-C-azido-P-phenyl-5'-cytidylyl-, 1-methylethyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 1186412-23-6 CAPLUS
 CN Glycine, N-[P(S)]-4'-C-azido-P-phenyl-5'-cytidylyl-, 1-methylethyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 1186412-24-7 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, butyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1186412-25-8 CAPLUS
 CN L-Phenylalanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1186412-26-9 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, phenyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1186412-28-1 CAPLUS
 CN L-Alanine, N-[4'-C-azido-P-(2-chlorophenyl)-5'-cytidylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1186412-29-2 CAPLUS
 CN L-Alanine, N-[4'-C-azido-P-(3-chlorophenyl)-5'-cytidylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1186412-30-5 CAPLUS
 CN L-Alanine, N-[4'-C-azido-P-(4-chlorophenyl)-5'-cytidylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1186412-31-6 CAPLUS
 CN L-Alanine, N-[4'-C-azido-P-(2-methoxyphenyl)-5'-cytidylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1186412-32-7 CAPLUS
 CN L-Alanine, N-[4'-C-azido-P-(3-methoxyphenyl)-5'-cytidylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1186412-33-8 CAPLUS
 CN L-Alanine, N-[4'-C-azido-P-(2-methylphenyl)-5'-cytidylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1186412-34-9 CAPLUS
 CN L-Alanine, N-[4'-C-azido-P-(4-methylphenyl)-5'-cytidylyl]-, phenylmethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1186412-35-0 CAPLUS

CN L-Alanine, N-[4'-C-azido-P-(4-bromophenyl)-5'-cytidylyl]-, phenylmethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1186412-37-2 CAPLUS

CN L-Alanine, N-[4'-C-azido-P-(3,4-dichlorophenyl)-5'-cytidylyl]-, phenylmethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1186412-38-3 CAPLUS


CN L-Alanine, N-[4'-C-azido-P-(4-methylphenyl)-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1186412-39-4 CAPLUS
 CN L-Alanine, N-[4'-C-azido-P-(2,6-dimethoxyphenyl)-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1186412-40-7 CAPLUS
 CN L-Alanine, N-[[P(R)]-4'-C-azido-P-1-naphthalenyl-5'-cytidylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1186412-41-8 CAPLUS
 CN L-Alanine, N-[[P(S)]-4'-C-azido-P-1-naphthalenyl-5'-cytidylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1186412-42-9 CAPLUS
 CN L-Alanine, N-[[P(R)]-4'-C-azido-P-2-naphthalenyl-5'-cytidylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1186412-43-0 CAPLUS
 CN L-Alanine, N-[{[P(S)]-4'-C-azido-P-2-naphthalenyl-5'-cytidylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:296890 CAPLUS
 DN 150:322627
 TI Method of treating cancer by administration of 5-substituted nucleosides
 IN Fahrig, Rudolf; Heinrich, Joerg-Christian
 PA Resprotect, GmbH, Germany
 SO U.S. Pat. Appl. Publ., 35pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20090068286	A1	20090312	US 2007-853540	20070911
CA 2601558	A1	20090311	CA 2007-2601558	20070911
PRAI US 2007-853540	T0	20070911		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 AB The invention relates to methods of administration of at least one overexpression inhibitor of DNA repair genes and/or oncogenes (e.g., (E)-5-(2-bromoethyl)-2'-deoxyuridine (BVDU), or a prodrug, or salt thereof) to increase the cytotoxic effect of a cytostatic or cytotoxic chemotherapeutic agent during and/or after chemotherapy, e.g., in the treatment of cancer.

IT 232925-18-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (method of treating cancer by administration of 5-substituted nucleosides)

RN 232925-18-7 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)



Absolute stereochemistry.
 Double bond geometry as shown.



L4 ANSWER 7 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:1215396 CAPLUS
 DN 149:426212
 TI Preparation of nucleoside phosphoramidate prodrugs as antiviral agents
 IN Sofia, Michael J.; Du, Jinfa; Wang, Peiyuan; Nagarathnam, Dhanapalan
 PA Pharmasset, Inc., USA
 SO PCT Int. Appl., 751 pp., Chemical Indexing Equivalent to 152:144974 (US)
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008121634	A2	20081009	WO 2008-US58183	20080326
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 20100016251	A1	20100121	US 2008-53015	20080321
	AU 2008232827	A1	20081009	AU 2008-232827	20080326
	CA 2682230	A1	20081009	CA 2008-2682230	20080326
	KR 2010016041	A	20100212	KR 2009-722652	20080326
	MX 2009010401	A	20091110	MX 2009-10401	20090928
PRAI	US 2007-909315P	P	20070330		
	US 2007-982309P	P	20071024		
	US 2008-53015	A	20080321		
	WO 2008-US58183	W	20080326		
OS	MARPAT 149:426212				
GI					



AB Disclosed herein are nucleoside phosphoramidates prodrugs I, wherein R and R₃ are independently H, alkyl, cycloalkyl, alkylamine, hydroxyalkyl, CH₂SH, alkyl-sulfonyl, (CH₂)₃NHC(=NH)NH₂, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, acyl, aryl, aryl-alkyl; R₃ and R both are alkyl; R₃ and R together are alkylidene so as to form a spiro ring; R₃ is H and R and R₂ together are (CH₂)_n so as to form a cyclic ring that includes the adjoining N and C atoms; R is H and R₃ and R₂ together are (CH₂)_n so as to form a cyclic ring; that includes the adjoining N and C atoms, n is 2 to 4; one of R and R₃ is H and the other is R₃ CH₃, Et, CH(CH₃)₂, CH₂CH(CH₃)₂, CH(CH₃)CH₂CH₃, CH₂Ph, CH₂-indol-3-yl, -CH₂CH₂SCH₃, CH₂CO₂H, CH₂C(O)NH₂, CH₂CH₂COOH, CH₂CH₂C(O)NH₂, CH₂CH₂CH₂CH₂NH₂, -CH₂CH₂CH₂NHC(NH)NH₂, CH₂-imidazol-4-yl, CH₂OH, CH(OH)CH₃, CH₂((4'-OH)-Ph), CH₂SH, cycloalkyl; R₁ is H, alkyl, cycloalkyl, aryl; R₂ is H, alkyl; R, R₂ and R₃ together are (CH₂)_n; R₄ is H, alkyl, alkoxy, alkylamino, halo, halo-alkyl, cycloalkyl, aminoacyl, aryl, heterocycle; R₅ is H, alkyl, CN, vinyl, hydroxy-alkyl, CH₂OH, CH₂F, CH₂CN, CH₂NH₂, CH₂NHMe, CH₂NMe₂, alkyne; R₆ is H, Me, CH₂F, CHF₂, CF₃, F, CN; X is H, OH, F, OMe, halogen, NH₂, N₃; Y is OH, H, alkyl, alkenyl, alkynyl, vinyl, N₃, CN, halo, oxycarbonyl sulfonyl, were prepared and tested as antiviral agents. Thus, nucleoside II was prepared and tested as antiviral agent for the treatment of any condition the result of an infection by hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus or Japanese encephalitis virus.

IT

1015255-46-5P	1064684-23-6P	1064684-24-7P
1064684-25-8P	1064684-28-1P	1064684-29-2P
1064684-30-5P	1064684-32-7P	1064684-33-8P
1064684-36-1P	1064684-37-2P	1064684-38-3P
1064684-41-8P	1064684-42-9P	1064684-43-0P
1064684-44-1P	1064684-45-2P	1064684-46-3P
1064684-47-4P	1064684-48-5P	1064684-49-6P
1064684-50-9P	1064684-52-1P	1064684-53-2P
1064684-54-3P	1064684-55-4P	1064684-56-5P
1064684-57-6P	1064684-58-7P	1064684-59-8P
1064684-60-1P	1064684-61-2P	1064684-62-3P
1064684-63-4P	1064684-64-5P	1064684-66-7P
1064684-67-8P	1064684-68-9P	1064684-69-0P
1064684-70-3P	1064684-71-4P	1064684-72-5P
1064684-73-6P	1064684-74-7P	1064684-75-8P
1064684-76-9P	1064684-77-0P	1064684-78-1P
1064684-79-2P	1064684-80-5P	1064684-81-6P
1064684-82-7P	1064684-85-0P	1064684-88-3P
1064684-92-9P	1064685-44-4P	1064685-46-6P
1064685-47-7P		


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nucleoside phosphoramidate prodrugs as antiviral agents)

RN 1015255-46-5 CAPLUS


CN L-Alanine, N-[2' R]-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-23-6 CAPLUS
 CN L-Valine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-24-7 CAPLUS
 CN L-Valine, N-[(2'R)-P-(4-bromophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1064684-25-8 CAPLUS
 CN L-Alanine, N-[(2'R)-P-(4-bromophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-28-1 CAPLUS
 CN L-Valine, N-[(2'R)-P-(4-bromophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-

cytidylyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-29-2 CAPLUS

CN L-Valine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-cytidylyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-30-5 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-32-7 CAPLUS

CN Glycine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-33-8 CAPLUS


CN L-Alanine, N-[(2'R)-2'-deoxy-P-(2,4-dichlorophenyl)-2'-fluoro-2'-methyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-36-1 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, butyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-37-2 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-38-3 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-(4-fluorophenyl)-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1064684-41-8 CAPLUS
 CN L-Alanine, N-[(2'R)-P-(4-chlorophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-42-9 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-P-(3,4-dichlorophenyl)-2'-fluoro-2'-methyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-43-0 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 1-methylpropyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-44-1 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-45-2 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-P-(4-methoxyphenyl)-2'-methyl-5'-

uridylyl]-, butyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-46-3 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-P-(4-fluorophenyl)-2'-methyl-5'-uridylyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-47-4 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-P-(4-fluorophenyl)-2'-methyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-48-5 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-P-(4-fluorophenyl)-2'-methyl-5'-uridylyl]-, phenylmethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-49-6 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-P-(4-methoxyphenyl)-2'-methyl-5'-uridyl]-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-50-9 CAPLUS

CN L-Alanine, N-[(2'R)-P-(2-chlorophenyl)-2'-deoxy-2'-fluoro-5'-uridyl]-, phenylmethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-52-1 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-P-(2,4-dichlorophenyl)-2'-fluoro-5'-uridyl]-, butyl ester (CA INDEX NAME)


Absolute stereochemistry.



10/560, 887


RN 1064684-53-2 CAPLUS
CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-(4-methylphenyl)-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-54-3 CAPLUS
CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-P-(4-fluorophenyl)-2'-methyl-5'-uridylyl]-, butyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-55-4 CAPLUS
CN L-Alanine, N-[(2'R)-2'-deoxy-P-(3,4-dichlorophenyl)-2'-fluoro-2'-methyl-5'-uridylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-56-5 CAPLUS
CN L-Alanine, N-[(2'R)-P-(2-chlorophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-57-6 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-(4-methoxyphenyl)-5'-uridylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-58-7 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, pentyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1064684-59-8 CAPLUS
 CN L-Alanine, N-[[P(R),2'R]-P-(4-chlorophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-60-1 CAPLUS
 CN L-Alanine, N-[(2'R)-P-(4-chlorophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-

uridylyl]-, butyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-61-2 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-62-3 CAPLUS

CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-(4-methylphenyl)-5'-uridylyl]-, butyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1064684-63-4 CAPLUS


CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-(4-methylphenyl)-5'-uridylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-64-5 CAPLUS
 CN Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, 5'-[phenyl N-[(1S)-1-(methoxycarbonyl)propyl]phosphoramidate], (2'R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-66-7 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, (4-fluorophenyl)methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-67-8 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 3-methylbutyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-68-9 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-P-(3,4-dichlorophenyl)-2'-fluoro-2'-methyl-5'-uridylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-69-0 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, cyclohexyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-70-3 CAPLUS
 CN D-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, butyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-71-4 CAPLUS
 CN D-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-72-5 CAPLUS
 CN D-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-73-6 CAPLUS
 CN L-Alanine, N-[({2'R},{3'R})-P-(2-chlorophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, butyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-74-7 CAPLUS
 CN L-Alanine, N-[({2'R},{3'R})-P-(4-bromophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-75-8 CAPLUS
 CN L-Alanine, N-[({2'R},{3'R})-2'-deoxy-2'-fluoro-P-(4-fluorophenyl)-2'-methyl-5'-uridylyl]-, cyclohexyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-76-9 CAPLUS
 CN L-Alanine, N-[(2'R)-P-(4-bromophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, cyclohexyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-77-0 CAPLUS
 CN Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, 5'-[phenyl N-[(1S)-1-[(1-methylethoxy)carbonyl]propyl]phosphoramidate], (2'R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-78-1 CAPLUS
 CN Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, 5'-[phenyl N-[(1S)-1-[(cyclohexyloxy)carbonyl]propyl]phosphoramidate], (2'R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-79-2 CAPLUS
 CN Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, 5'-[4-fluorophenyl N-[(1S)-1-[(cyclohexyloxy)carbonyl]propyl]phosphoramidate], (2'R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-80-5 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 2-fluoroethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-81-6 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 2,2-difluoroethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-82-7 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-85-0 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 2-fluoro-1-(fluoromethyl)ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-88-3 CAPLUS
 CN L-Alanine, N-[({2'R}-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl)-cyclopropylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064684-92-9 CAPLUS
 CN Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, 5'-[phenyl N-[(1S)-1-[(cyclopentyloxy)carbonyl]propyl]phosphoramidate], (2'R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1064685-44-4 CAPLUS
 CN Glycine, N-[{P(S),2'R}-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064685-46-6 CAPLUS
 CN L-Alanine, N-[{P(S),2'R}-P-(4-chlorophenyl)-2'-deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1064685-47-7 CAPLUS
 CN L-Alanine, N-[(P(S)2)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, cyclohexyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 1064684-27-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of nucleoside phosphoramidate prodrugs as antiviral agents)
 RN 1064684-27-0 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-cytidylyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 8 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:805636 CAPLUS
 DN 149:119579
 TI Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infections
 IN Meppen, Malte; Narjes, Frank; Pacini, Barbara; Gardelli, Cristina;
 Durette, Philippe L.
 PA Merck & Co., Inc., USA; Istituto di Ricerche di Biologia Molecolare P.
 Angeletti S.p.A.
 SO PCT Int. Appl., 55pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI WO 2008079206 A1 20080703 WO 2007-US25637 20071214
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,

CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
 GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
 KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
 PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM
 AU 2007338899 A1 20080703 AU 2007-338899 20071214
 CA 2672613 A1 20080703 CA 2007-2672613 20071214
 EP 2120565 A1 20091125 EP 2007-853391 20071214
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR
 US 20100022468 A1 20100128 US 2009-519038 20090612
 PRAI US 2006-876034P P 20061220
 WO 2007-US25637 W 20071214

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OS MARPAT 149:119579
 GI



AB The invention discloses nucleoside cyclic phosphoramidates I, II (R1= H, Me, fluoromethyl; R2= F, OR3; R3= H, Me, C1-16 alkylcarbonyl, etc.; R4= H, C1-5 alkyl, Ph, etc; R5= H, Me; R6= H, C1-16 alkyl, Ph, adamantly, etc.; R9= H, C1-8 alkylcarbonyl, C1-8 alkyloxycarbonyl, etc.; R10= H, C1-8 alkyl, C1-8 alkylcarbonyl), precursors to inhibitors of RNA-dependent RNA viral polymerase. The compds. are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for treating RNA-dependent RNA viral infections. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase and precursors to inhibitors of HCV replication and/or are useful for the treatment of hepatitis C infection. The invention also describes pharmaceutical compns. containing such nucleoside cyclic phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infections, in particular HCV infection. Also disclosed are methods for inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with nucleoside cyclic phosphoramidates of the invention.


IT 1035638-03-9P 1035638-05-1P 1035638-12-0P
 1035638-18-6P 1035638-22-2P 1035638-24-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (nucleoside cyclic phosphoramidates for treatment of hepatitis C and other RNA-dependent RNA viral infections)

RN 1035638-03-9 CAPLUS
 CN L-Alanine, N-[[P(R)]-P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, butyl ester, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

10/560, 887


CRN 1035638-02-8
CMF C23 H32 Cl N4 O9 P

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 1035638-05-1 CAPLUS

CN L-Alanine, N-[P(R)]-P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl-, ethyl ester, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 1035638-04-0
CMF C21 H28 Cl N4 O9 P

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1035638-12-0 CAPLUS

McIntosh


10/560,887

CN L-Alanine, N-[P(S)]-P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl-, heptyl ester, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 1035638-11-9
CMF C26 H38 Cl N4 O9 P

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 1035638-18-6 CAPLUS

CN L-Alanine, N-[P(S)]-P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl-, butyl ester, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 1035638-17-5
CMF C23 H32 Cl N4 O9 P

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1035638-22-2 CAPLUS


CN L-Alanine, N-[[P(S)]-P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, ethyl ester, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1035638-21-1

CMF C21 H28 Cl N4 O9 P


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 1035638-24-4 CAPLUS


CN L-Alanine, N-[[P(R)]-P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, heptyl ester, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1035638-23-3


CMF C26 H38 Cl N4 O9 P

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L4 ANSWER 9 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:130979 CAPLUS
 DN 148:393762
 TI The mechanism of action of β -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine involves a second metabolic pathway leading to β -D-2'-deoxy-2'-C-methyluridine 5'-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase
 AU Murakami, Eisuke; Niu, Congrong; Bao, Haiying; Steuer, Holly M.
 Miclochick; Whitaker, Tony; Nachman, Tammy; Sofia, Michael A.; Wang, Peiyuan; Otto, Michael J.; Furman, Phillip A.
 CS Pharmasset, Inc., Princeton, NJ, 08540, USA
 SO Antimicrobial Agents and Chemotherapy (2008), 52(2), 458-464
 CODEN: AMACQ; ISSN: 0066-4804
 PB American Society for Microbiology
 DT Journal
 LA English
 AB β -D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) is a potent inhibitor of hepatitis C virus (HCV) RNA replication in an HCV replicon assay. The 5'-triphosphate of PSI-6130 is a competitive inhibitor of the HCV RNA-dependent RNA polymerase (RdRp) and acts as a nonobligate chain terminator. Recently, it has been shown that the metabolism of PSI-6130 also results in the formation of the 5'-triphosphate of the uridine congener, β -D-2'-deoxy-2'-fluoro-2'-C-methyluridine (PSI-6206; RO2433). Here we show that the formation of the 5'-triphosphate of RO2433 (RO2433-TP) requires the deamination of PSI-6130 monophosphate and that RO2433 monophosphate is subsequently phosphorylated to the corresponding di- and triphosphates by cellular UMP-CMP kinase and nucleoside diphosphate kinase, resp. RO2433-TP is a potent inhibitor of the HCV RdRp; however, both enzymic and cell-based assays show that PSI-6130 triphosphate is a more potent inhibitor of the HCV RdRp than RO2433-TP.
 IT 1015255-46-5P, PSI 7672
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prodrug PSI-6130 metabolism yields two potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase)
 RN 1015255-46-5 CAPLUS
 CN L-Alanine, N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
 RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 10 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:40834 CAPLUS
 DN 149:258613
 TI Synthesis and Biological Evaluation of LNA Phosphoramidates
 AU Jensen, Jacob; Sjogren, Gitte; Hansen, Jens Bo; Rosenbohm, Christoph;
 Koch, Troels
 CS Santaris Pharma A/S, Hoersholm, Den.
 SO Nucleosides, Nucleotides & Nucleic Acids (2008), 27(1), 37-42
 CODEN: NNNAFY; ISSN: 1525-7770
 PB Taylor & Francis, Inc.
 DT Journal
 LA English
 OS CASREACT 149:258613
 AB The synthesis of LNA (locked nucleic acid) phosphoramidates is presented. The LNA phosphoramidates were evaluated for their ability to inhibit cell proliferation of the human prostate cancer cell line 15PC3. A number of the LNA phosphoramidates showed cell proliferation inhibition determined by the MTS assay.
 IT 936616-55-6P 936616-56-7P 936616-57-8P
 936616-58-9P 936616-59-0P 936616-60-3P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis and biol. evaluation of locked nucleic acid (LNA)
 phosphoramidates as antitumor agents)
 RN 936616-55-6 CAPLUS
 CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, methyl ester, 4'-ester with
 1-[2,5-anhydro-4-C-(hydroxymethyl)- α -L-lyxofuranosyl]-5-methyl-
 2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 936616-56-7 CAPLUS
 CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, phenylmethyl ester, 4'-ester
 with 1-[2,5-anhydro-4-C-(hydroxymethyl)- α -L-lyxofuranosyl]-5-methyl-
 2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 936616-57-8 CAPLUS
 CN L-Alanine, N-[(4-chlorophenoxy)hydroxyphosphinyl]-, methyl ester, 4'-ester with 1-[2,5-anhydro-4-C-(hydroxymethyl)- α -L-lyxofuranosyl]-5-methyl-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 936616-58-9 CAPLUS
 CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, methyl ester, 4'-ester with 1-[2,5-anhydro-4-C-(hydroxymethyl)- β -D-lyxofuranosyl]-5-methyl-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 936616-59-0 CAPLUS
 CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, phenylmethyl ester, 4'-ester with 1-[2,5-anhydro-4-C-(hydroxymethyl)- β -D-lyxofuranosyl]-5-methyl-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 936616-60-3 CAPLUS
 CN L-Alanine, N-[(4-chlorophenoxy)hydroxyporphinyl]-, methyl ester, 4'-ester
 with 1-[2,5-anhydro-4-C-(hydroxymethyl)- β -D-lyxofuranosyl]-5-methyl-
 2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2007:1224266 CAPLUS
 DN 148:79258
 TI Hydrolytic reactions of thymidine 5'-O-phenyl-N-alkylphosphoramides, models of nucleoside 5'-monophosphate prodrugs
 AU Ora, Mikko; Ojanperae, Jarno; Loennberg, Harri
 CS Department of Chemistry, University of Turku, Turku, 20014, Finland
 SO Chemistry--A European Journal (2007), 13(30), 8591-8599
 CODEN: CEUJED; ISSN: 0947-6539
 PB Wiley-VCH Verlag GmbH & Co. KGaA
 DT Journal
 LA English
 OS CASREACT 148:79258
 GI



AB To obtain detailed data on the kinetics of hydrolytic reactions of triester-like nucleoside 5'-O-aryl-N-alkylphosphoramides, potential prodrugs of antiviral nucleoside monophosphates, the hydrolysis of diastereomeric (Rp/Sp) thymidine 5'-[O-phenyl-N-[(1S)-2-oxo-2-methoxy-1-methylethyl]phosphoramidate} (I) (R1 = H, R2 = Me, R3 = Ph), a phosphoramidate derived from the Me ester of L-alanine, has been followed by reversed-phase HPLC over the range from pH 0 to pH 8 at 90°C.

According to the time-dependent product distributions, the hydrolysis of I ($R_1 = H$, $R_2 = Me$, $R_3 = Ph$) proceeds at pH < 4 by two parallel routes, namely by nucleophilic displacement of the alaninyl ester moiety by a water mol. and by hydrolysis of the carboxylic ester linkage that allows intramol. attack of the carboxy group on the phosphorus atom, thereby resulting in the departure of either thymidine or phenol without marked accumulation of any intermediates. Both routes represent about half of the overall disappearance of I ($R_1 = H$, $R_2 = Me$, $R_3 = Ph$). The departure of phenol eventually leads to the formation of thymidine 5'-phosphate. At pH > 5, the predominant reaction is hydrolysis of the carboxylic ester linkage followed by intramol. displacement of a phenoxide ion by the carboxylate ion and hydrolysis of the resulting cyclic mixed anhydride into an acyclic diester-like thymidine 5'-phosphoramidate. The latter product accumulated quant. without any indication of further decomposition. Hydroxide-ion-catalyzed P-OPh bond cleavage of the starting material I occurred as a side reaction. Comparative measurements with thymidine 5'-{N-[$(1S)$ -2-oxo-2-methoxy-1-methylethyl]phosphoramidate} I ($R_1 = Me$, $R_2 = H$, $R_3 = H$) revealed that, under acidic conditions, this diester-like compound is hydrolyzed by P-N bond cleavage three orders of magnitude more rapidly than the triester-like 3. At pH > 5, the stability order is reversed, with I ($R_1 = H$, $R_2 = Me$, $R_3 = Ph$) being hydrolyzed six times as rapidly as I ($R_1 = Me$, $R_2 = H$, $R_3 = H$). Mechanisms of the partial reactions are discussed.


IT 960509-75-5P

RL: PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(kinetics of hydrolytic bond cleavage of thymidine Ph oxomethoxymethyl ethyl phosphoramides derived from Me ester of alanine)

RN 960509-75-5 CAPLUS

CN L-Alanine, N-[[P(S)]-P-phenyl-5'-thymidylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




IT 960509-79-9P

RL: PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(preparation of thymidine phosphoramidates by nucleophilic displacement of alaninyl ester moiety by water mol. and by hydrolysis of carboxylic ester linkage)

RN 960509-79-9 CAPLUS

CN L-Alanine, N-[[P(R)]-P-phenyl-5'-thymidylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2007:941862 CAPLUS
 DN 147:301398
 TI Preparation of nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
 IN Maccoss, Malcolm; Olsen, David B.; Donghi, Monica; Gardelli, Cristina; Harper, Steven; Meppen, Malte; Narjes, Frank; Pacini, Barbara
 PA Merck & Co., Inc., USA; Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
 SO PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007095269	A2	20070823	WO 2007-US3862	20070212
	WO 2007095269	A3	20071115		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	AU 2007215114	A1	20070823	AU 2007-215114	20070212
	CA 2637879	A1	20070823	CA 2007-2637879	20070212
	EP 1987050	A2	20081105	EP 2007-750684	20070212
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2009526850	T	20090723	JP 2008-555315	20070212
	CN 101384609	A	20090311	CN 2007-80005274	20080813
PRAI	US 2006-773009P	P	20060214		
	US 2006-832832P	P	20060724		
	WO 2007-US3862	W	20070212		
OS	MARPAT 147:301398				
GI					



AB The present invention provides nucleoside aryl phosphoramidates I, wherein Ar is Ph; R1 is H, F; R2 is F, OMe, OH, OR; R and R3 are independently alkyl-carbonyl, alkenyl-carbonyl, alkyloxy-carbonyl, cycloalkyl-carbonyl, cycloalkyloxy-carbonyl, amino acyl; R4 is H, alkyl, Ph, benzyl; R5 is H, Me; R4R5 together with the carbon atom to which they are attached form 3- to 6-membered aliphatic spiro-cyclic ring system; R6 is H, alkyl, alkenyl, cycloalkyl, Ph, benzyl, adamantyl; R7 is H, alkyl-carbonyl, alkyloxy-carbonyl, were prepared as precursors to inhibitors of RNA-dependent RNA viral polymerase. Thus,.. These compds. are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly

useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compns. containing such nucleoside aryl phosphoramides alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramides of the present invention.

IT 946511-06-4P 946511-08-6P 946511-10-0P
 946511-12-2P 946511-14-4P 946511-16-6P
 946511-18-8P 946511-20-2P 946511-21-3P
 946511-22-4P 946511-23-5P 946511-25-7P
 946511-26-8P 946511-27-9P 946511-28-0P
 946511-29-1P 946511-30-4P 946511-31-5P
 946511-32-6P 946511-33-7P 946511-34-8P
 946511-35-9P 946511-36-0P 946511-37-1P
 946511-38-2P 946511-39-3P 946511-40-6P
 946511-41-7P 946511-42-8P 946511-43-9P
 946511-44-0P 946511-45-1P 946511-46-2P
 946511-47-3P 946511-48-4P 946511-49-5P
 946511-50-8P 946511-51-9P 946511-52-0P
 946511-53-1P 946511-54-2P 946511-55-3P
 946511-56-4P 946511-57-5P 946511-58-6P
 946511-59-7P 946511-60-0P 946511-61-1P
 946511-62-2P 946511-63-3P 946511-64-4P
 946511-66-6P 946511-67-7P 946511-68-8P
 946511-69-9P 946511-70-2P 946511-71-3P
 946511-72-4P 946511-74-6P 946511-76-8P
 946511-78-0P 946511-79-1P 946511-80-4P
 946511-81-5P 946511-82-6P 946511-95-1P
 946512-01-2P 946512-02-3P 946512-04-5P
 946512-06-7P 946512-07-8P 946512-08-9P
 946512-09-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nucleoside aryl phosphoramides for treatment of RNA-dependent RNA viral infection)

RN 946511-06-4 CAPLUS


CN L-Alanine, N-[[P(R)]-2'-C-methyl-P-1-naphthalenyl-5'-cytidylyl]-, butyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 946511-05-3

CMF C27 H35 N4 O9 P


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 946511-08-6 CAPLUS
 CN L-Alanine, N-(2'-C-methyl-P-1-naphthalenyl-5'-cytidylyl)-, ethyl ester,
 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 946511-07-5
 CMF C25 H31 N4 O9 P

Absolute stereochemistry.



CM 2


CRN 76-05-1
 CMF C2 H F3 O2

RN 946511-10-0 CAPLUS
 CN L-Alanine, N-[[P(R)]-P-[4-chloro-5-methyl-2-(1-methylethyl)phenyl]-2'-C-methyl-5'-cytidylyl]-, ethyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 946511-09-7
 CMF C25 H36 Cl N4 O9 P


Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 946511-12-2 CAPLUS
CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-,
(9Z)-9-octadecen-1-yl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 946511-11-1
CMF C37 H58 Cl N4 O9 PAbsolute stereochemistry.
Double bond geometry as shown.


CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 946511-14-4 CAPLUS
CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, ethyl ester,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 946511-13-3
CMF C21 H28 Cl N4 O9 P

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 946511-16-6 CAPLUS
 CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, 1-methylethyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 946511-15-5
CMF C22 H30 Cl N4 O9 P

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 946511-18-8 CAPLUS
 CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, butyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

10/560, 887


CRN 946511-17-7
CMF C23 H32 Cl N4 O9 P

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 946511-20-2 CAPLUS
CN Glycine, N-(2'-C-methyl-P-1-naphthalenyl-5'-cytidylyl)-, butyl ester,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 946511-19-9
CMF C26 H33 N4 O9 P

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 946511-21-3 CAPLUS
CN L-Alanine, N-[P(R)]-2'-C-methyl-P-phenyl-5'-cytidylyl-, 2-ethylbutyl

McIntosh

ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-22-4 CAPLUS

CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, 2,2-dimethylpropyl
ester (CA INDEX NAME)

Absolute stereochemistry.



RN 946511-23-5 CAPLUS


CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, 2,2-dimethylpropyl
ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 946511-22-4

CMF C24 H35 N4 O9 P


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 946511-25-7 CAPLUS

CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, octyl ester,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 946511-24-6
CMF C27 H41 N4 O9 P

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 946511-26-8 CAPLUS
CN L-Alanine, N-[(P(R)]-2'-C-methyl-P-phenyl-5'-cytidylyl)-, 2-propylpentyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-27-9 CAPLUS
CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, 2-(hexyloxy)ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-28-0 CAPLUS
CN L-Alanine, N-(P-1H-indol-5-yl-2'-C-methyl-5'-cytidylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-29-1 CAPLUS
 CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-30-4 CAPLUS
 CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, cyclopropylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-31-5 CAPLUS
 CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-32-6 CAPLUS
 CN L-Alanine, N-[2'-C-methyl-P-[4-(trifluoromethyl)phenyl]-5'-cytidylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-33-7 CAPLUS
 CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, propyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-34-8 CAPLUS
 CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, tricyclo[3.3.1.13,7]dec-2-yl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-35-9 CAPLUS
 CN L-Alanine, N-[P-(2-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, methyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-36-0 CAPLUS
 CN L-Alanine, N-[P-(4-bromophenyl)-2'-C-methyl-5'-cytidylyl]-, methyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-37-1 CAPLUS
 CN L-Alanine, N-[P-(4-methoxyphenyl)-2'-C-methyl-5'-cytidylyl]-, methyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-38-2 CAPLUS
 CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-39-3 CAPLUS
 CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, 2-propen-1-yl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-40-6 CAPLUS
 CN L-Alanine, N-[2'-C-methyl-P-[4-(trifluoromethoxy)phenyl]-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-41-7 CAPLUS
 CN L-Alanine, N-(2'-C-methyl-P-2-naphthalenyl-5'-cytidylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 946511-42-8 CAPLUS
 CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, 2,2-difluoroethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-43-9 CAPLUS

CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, phenyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 946511-44-0 CAPLUS

CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, phenylmethyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 946511-45-1 CAPLUS

CN L-Alanine, N-[P-(2-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, butyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 946511-46-2 CAPLUS


CN L-Alanine, N-[P-(4-chloro-1-naphthalenyl)-2'-C-methyl-5'-cytidylyl]-,
butyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-47-3 CAPLUS
CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, cyclohexyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-48-4 CAPLUS
CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, octyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 946511-49-5 CAPLUS
CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, cyclopentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-50-8 CAPLUS

CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, 2-ethylbutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-51-9 CAPLUS

CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, 1-naphthalenyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-52-0 CAPLUS

CN L-Alanine, N-[2'-C-methyl-P-[5-methyl-2-(1-methylethyl)phenyl]-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-53-1 CAPLUS

CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, 4-methylpentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-54-2 CAPLUS

CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, 3-methylbutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-55-3 CAPLUS

CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, heptyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-56-4 CAPLUS


CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, 2-methoxyethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-57-5 CAPLUS
 CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-,
 3-methoxypropyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-58-6 CAPLUS
 CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, butyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 946511-59-7 CAPLUS
 CN L-Alanine, N-[2'-C-methyl-P-(2-methylphenyl)-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-60-0 CAPLUS
 CN L-Alanine, N-[P-[4-chloro-5-methyl-2-(1-methylethyl)phenyl]-2'-C-methyl-5'-

cytidylyl]-, butyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-61-1 CAPLUS

CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, 2-ethylbutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-62-2 CAPLUS

CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, 4-methylpentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-63-3 CAPLUS

CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-64-4 CAPLUS

CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, 3-methylbutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-66-6 CAPLUS

CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, cyclopentylmethyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 946511-67-7 CAPLUS

CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, cyclohexylmethyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 946511-68-8 CAPLUS

CN L-Alanine, N-(2'-C-methyl-P-phenyl-5'-cytidylyl)-, propyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 946511-69-9 CAPLUS


CN Cytidine, 2'-C-methyl-, 5'-[4-chlorophenyl-N-[1-(methoxycarbonyl)cyclopentyl]phosphoramidate] (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-70-2 CAPLUS
 CN Cytidine, 2'-C-methyl-, 5'-[4-chlorophenyl]
 N-[(1S)-1-(ethoxycarbonyl)propyl]phosphoramidate] (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-71-3 CAPLUS
 CN Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-2-methyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-72-4 CAPLUS
 CN L-Leucine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-74-6 CAPLUS
 CN L-Norleucine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-76-8 CAPLUS
 CN Glycine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-78-0 CAPLUS
 CN Cytidine, 2'-C-methyl-, 5'-[4-chlorophenyl N-[(1S)-2-ethoxy-2-oxo-1-phenylethyl]phosphoramidate] (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-79-1 CAPLUS
 CN L-Norvaline, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-80-4 CAPLUS
 CN L-Methionine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-81-5 CAPLUS
 CN L-Tryptophan, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-82-6 CAPLUS
 CN L-Alanine, N-[P-[2-(methoxycarbonyl)phenyl]-2'-C-methyl-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946511-95-1 CAPLUS
 CN L-Alanine, N-[P(R)]-P-[1-[(1,1-dimethylethoxy)carbonyl]-1H-indol-5-yl]-2'-C-methyl-5'-cytidylyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946512-01-2 CAPLUS
 CN L-Alanine, N-[P-(4-chlorophenyl)-2'-C-methyl-5'-cytidylyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 946512-02-3 CAPLUS
 CN L-Alanine, N-(2'-C-methyl-P-1-naphthalenyl-5'-cytidylyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946512-04-5 CAPLUS
 CN L-Alanine, N-[P(S)]-2'-C-methyl-P-1-naphthalenyl-5'-cytidylyl-, butyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 946512-03-4
 CMF C27 H35 N4 O9 P

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 946512-06-7 CAPLUS
 CN L-Alanine, N-[[P(S)]-P-[4-chloro-5-methyl-2-(1-methylethyl)phenyl]-2'-C-methyl-5'-cytidylyl]-, ethyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 946512-05-6
CMF C25 H36 Cl N4 O9 P

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 946512-07-8 CAPLUS
 CN L-Alanine, N-[[P(S)]-2'-C-methyl-P-phenyl-5'-cytidylyl]-, 2-ethylbutyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 946512-08-9 CAPLUS
 CN L-Alanine, N-[[P(S)]-2'-C-methyl-P-phenyl-5'-cytidylyl]-, 2-propylpentyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 946512-09-0 CAPLUS
 CN L-Alanine, N-[[P(S)]-P-[1-[(1,1-dimethylethoxy)carbonyl]-1H-indol-5-yl]-2'-C-methyl-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 13 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2007:619578 CAPLUS

DN 147:46112

TI Treatment of cancer and other diseases

IN Habib, Nabil

PA Nabil Habib Lab, Lebanon; Vianova Labs, Inc.

SO PCT Int. Appl., 86pp.

CODEN: PIXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007064691	A1	20070607	WO 2006-US45665	20061130
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 CA 2632903 A1 20070607 CA 2006-2632903 20061130
 EP 1968607 A1 20080917 EP 2006-844623 20061130
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
 US 20090226431 A1 20090910 US 2009-85892 20090306
 PRAI US 2005-741725P P 20051202
 WO 2006-US45665 W 20061130

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 147:46112

AB The present invention relates to a novel compound (e.g., 24-ethyl-cholestane-3 β ,5 α ,6 α -triol), its production, its use, and to methods of treating neoplasms and other tumors as well as other diseases including hypercholesterolemia, autoimmune diseases, viral diseases (e.g., hepatitis B, hepatitis C, or HIV), and diabetes.

IT 232925-18-7, Thymectacin


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

RN 232925-18-7 CAPLUS

CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2007:538915 CAPLUS

DN 146:522025

TI Preparation of locked nucleic acid nucleoside phosphoramidates for use as therapeutic prodrugs in the treatment of cancer

IN Rosenbohm, Christoph; Jensen, Jacob; Koch, Troels

PA Santaris Pharma A/S, Den.

SO PCT Int. Appl., 34pp.

CODEN: PIXXD2



DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007054100	A2	20070518	WO 2006-DK627	20061113
	WO 2007054100	A3	20071004		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,			

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 EP 2099461 A2 20090916 EP 2006-805565 20061113
 R: AT, BE, BG, CH, CY, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
 PRAI WO 2006-DK627 W 20061113
 OS CASREACT 146:522025; MARPAT 146:522025
 GI




AB LNA nucleoside phosphoramidites I, wherein B is a nucleobase; Ar is an (un)substituted aryl group; X can be O, S, or an (un)substituted amino group; R1 is an alkyl, aryl or alkylaryl group; R2 and R3 are independently H, alkyl, aryl or an alkylene chain; R4 is an H, OH, amino, azido, halo, alkyl, alkoxy, nitro group, etc.; and the available stereocenters can be present in any orientation, are prepared as inhibitors or cell proliferation. Thus, II was prepared from (1S,3R,4R,7S)-3-(adenin-9-yl)-7-hydroxy-1-hydroxymethyl-2,5-dioxabicyclo[2.2.1]heptane and Ph-(Benzyl-O-L-alaninyl)phosphorchloridated and tested as an anticancer chemotherapeutic prodrug in an MTS assay (over 80% inhibition at 0.1 μ M after 24 h). Further, I were also tested in the same assay at concns. from 0.1 to 500 μ M for between 24 and 96 h. and displayed an inhibition ranging from 20 to over 90%. As a result I can be effectively used as a prodrug in the therapeutic treatment of variety of cancer cells, most notably lung cancer.

IT 936616-55-6P 936616-56-7P 936616-57-8P
 936616-58-9P 936616-59-0P 936616-60-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of locked nucleic acid nucleoside phosphoramidates for use as therapeutic prodrugs in the treatment of cancer)

RN 936616-55-6 CAPLUS
 CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, methyl ester, 4'-ester with 1-[2,5-anhydro-4-C-(hydroxymethyl)- α -L-lyxofuranosyl]-5-methyl-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)


Absolute stereochemistry.



RN 936616-56-7 CAPLUS

CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, phenylmethyl ester, 4'-ester with 1-[2,5-anhydro-4-C-(hydroxymethyl)- α -L-lyxofuranosyl]-5-methyl-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)


Absolute stereochemistry.



RN 936616-57-8 CAPLUS

CN L-Alanine, N-[4-chlorophenoxy]hydroxyphosphinyl-, methyl ester, 4'-ester with 1-[2,5-anhydro-4-C-(hydroxymethyl)- α -L-lyxofuranosyl]-5-methyl-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 936616-58-9 CAPLUS

CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, methyl ester, 4'-ester with 1-[2,5-anhydro-4-C-(hydroxymethyl)- β -D-lyxofuranosyl]-5-methyl-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

10/560, 887


Absolute stereochemistry.



RN 936616-59-0 CAPLUS

CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, phenylmethyl ester, 4'-ester with 1-[2,5-anhydro-4-C-(hydroxymethyl)-β-D-lyxofuranosyl]-5-methyl-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)


Absolute stereochemistry.



RN 936616-60-3 CAPLUS

CN L-Alanine, N-[(4-chlorophenoxy)hydroxyphosphinyl]-, methyl ester, 4'-ester with 1-[2,5-anhydro-4-C-(hydroxymethyl)-β-D-lyxofuranosyl]-5-methyl-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 15 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2007:538398 CAPLUS

DN 146:501355
 TI Phosphoramidate derivatives of FAU
 IN Shields, Anthony F.; Zemlicka, Jiri; Nimmagadda, Sridhar
 PA Wayne State University, USA
 SO PCT Int. Appl., 40pp.
 CODEN: PIXXD2

DT Patent
 LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007056596	A2	20070518	WO 2006-US43882	20061109
	WO 2007056596	A3	20070705		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	US 20080292553	A1	20081127	US 2008-92999	20080728
PRAI	US 2005-734804P	P	20051109		
	WO 2006-US43882	W	20061109		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 146:501355; MARPAT 146:501355

GI



AB Phosphoramidate derivs. of a furanosyluracil analog, FAU, (I) [R1 = H, F, alkyl; R4 = (un)substituted Ph; R2 and R3 = individually H, (un)substituted alkyl, alkoxy, alkylthio, Ph, aryloxy, cyano, alkoxy carbonyl, amino, alkylamido, alkylsulfonyl, arylsulfonyl, perfluoroalkylsulfonyl, alkylsulfinyl, arylsulfinyl, or R2 and R3 taken together with N are a heteroaryl or heterocyclic ring, and R2 and R3 are not H; R5 = F or F18] were prepared as effective intracellular deliver of FAU monophosphates to be converted to nucleoside monophosphates, which improves formation of nucleoside triphosphates and higher incorporation into DNA. The compds. of the invention can be used for cancer treatment. Thus, FAU [2,4(1H,3H)-pyrimidinedione, 1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)] in dry TFA was sonicated, and after addition of N-Me imidazole, a solution of Me chlorophenylphosphoryl P→N alaninate was added continuously over period of 4 h with continuous stirring to give after work up or FAU-PA [1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)-uracil-5'- (phenylmethoxyalaninyl phosphate)] in 62.5% yield and showed inhibition of tumor cell growth higher than FAU.

IT 936363-09-6P


RL: DGN (Diagnostic use); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phosphoramidate alaninyl derivs. of FAU as antitumor and imaging agents)

RN 936363-09-6 CAPLUS

CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, methyl ester, 5'-ester with 1-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)-2,4(1H,3H)-pyrimidinedione, labeled with tritium (CA INDEX NAME)

Absolute stereochemistry.



IT 256520-25-9P 936363-07-4P


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phosphoramidate alaninyl derivs. of FAU as antitumor and imaging agents)

RN 256520-25-9 CAPLUS

CN L-Alanine, N-(P-phenyl-5'-thymidylyl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 936363-07-4 CAPLUS

CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, methyl ester, 5'-ester with 1-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 16 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2007:299062 CAPLUS

DN 146:501313

TI Application of the Phosphoramidate ProTide Approach to 4'-Azidouridine Confers Sub-micromolar Potency versus Hepatitis C Virus on an Inactive Nucleoside

AU Perrone, Plinio; Luoni, Giovanna M.; Kelleher, Mary Rose; Daverio, Felice; Angell, Annette; Mulready, Sinead; Congiatu, Costantino; Rajyaguru, Sonal; Martin, Joseph A.; Leveque, Vincent; Le Pogam, Sophie; Najera, Isabel; Klumpp, Klaus; Smith, David B.; McGuigan, Christopher

CS Welsh School of Pharmacy, Cardiff University, Cardiff, CF10 3XF, UK

SO Journal of Medicinal Chemistry (2007), 50(8), 1840-1849

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

OS CASREACT 146:501313

AB The authors report the application of their phosphoramidate ProTide technol. to the ribonucleoside analog 4'-azidouridine to generate novel antiviral agents for the inhibition of hepatitis C virus (HCV). 4'-Azidouridine did not inhibit HCV, although 4'-azidocytidine was a potent inhibitor of HCV replication under similar assay conditions. However 4'-azidouridine triphosphate was a potent inhibitor of RNA synthesis by HCV polymerase, raising the question as to whether the phosphoramidate ProTide approach could effectively deliver 4'-azidouridine monophosphate to HCV replicon cells and unleash the antiviral potential of the triphosphate. Twenty-two phosphoramidates were prepared, including variations in the aryl, ester, and amino acid regions. A number of compds. showed sub-micromolar inhibition of HCV in cell culture without detectable cytotoxicity. These results confirm that phosphoramidate ProTides can deliver monophosphates of ribonucleoside analogs and suggest a potential path to the generation of novel antiviral agents against HCV infection. The generic message is that ProTide synthesis from inactive parent nucleosides may be a warranted drug discovery strategy.


IT 936334-98-4P 936334-99-5P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (lowest energy conformation; preparation and biol. activity of amino acid- and azidouridine-containing phosphoramidates as inhibitors of hepatitis C virus)

RN 936334-98-4 CAPLUS

CN L-Alanine, N-[{[P(R)]-4'-C-azido-P-1-naphthalenyl-5'-uridylyl}-, phenylmethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 936334-99-5 CAPLUS

CN L-Alanine, N-[{[P(S)]-4'-C-azido-P-1-naphthalenyl-5'-uridylyl}-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 926308-43-2P	926308-46-5P	926308-63-6P
926308-66-9P	926308-74-9P	926308-77-2P
926308-82-9P	926308-83-0P	926308-87-4P
926308-99-8P	926309-04-8P	926309-06-0P


926309-08-2P 926309-09-3P 926309-12-8P
 926309-21-9P 926309-73-1P 926309-75-3P
 936334-95-1P 936334-97-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and biol. activity of amino acid- and azidouridine-containing phosphoramides as inhibitors of hepatitis C virus)

RN 926308-43-2 CAPLUS

CN Uridine, 4'-C-azido-, 5'-[phenyl N-[1,1-dimethyl-2-oxo-2-(phenylmethoxy)ethyl]phosphoramidate] (CA INDEX NAME)


Absolute stereochemistry.



RN 926308-46-5 CAPLUS

CN Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-2-methyl-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 926308-63-6 CAPLUS

CN Glycine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, phenylmethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 926308-66-9 CAPLUS

CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-74-9 CAPLUS

CN L-Phenylalanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, ethyl ester (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 926308-77-2 CAPLUS

CN L-Phenylalanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, phenylmethyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 926308-82-9 CAPLUS

CN Uridine, 4'-C-azido-, 5'-[phenyl N-[1-(phenylmethoxy)carbonyl]cyclopentyl]phosphoramidate] (CA INDEX NAME)


Absolute stereochemistry.



RN 926308-83-0 CAPLUS

CN Uridine, 4'-C-azido-, 5'-[hydrogen N-[1-(ethoxycarbonyl)cyclopentyl]phosphoramidate] (CA INDEX NAME)


Absolute stereochemistry.



RN 926308-87-4 CAPLUS


CN L-Leucine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-99-8 CAPLUS
 CN L-Valine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-04-8 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-06-0 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-08-2 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-09-3 CAPLUS
 CN D-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-12-8 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-21-9 CAPLUS
 CN L-Methionine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-73-1 CAPLUS
 CN L-Glutamic acid, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, 1,5-diethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-75-3 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, butyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 936334-95-1 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, 1-methylpropyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 936334-97-3 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-1-naphthalenyl-5'-uridylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 27 THERE ARE 27 CAPLUS RECORDS THAT CITE THIS RECORD (27 CITINGS)
 RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2007:201671 CAPLUS
 DN 146:252063
 TI Preparation of amino acid-containing nucleotide phosphoramides as antiviral agents
 IN Klumpp, Klaus; Martin, Joseph Armstrong; McGuigan, Christopher; Smith, David Bernard
 PA F. Hoffmann-La Roche A.-G., Switz.
 SO PCT Int. Appl., 145pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007020193	A2	20070222	WO 2006-EP65021	20060803
	WO 2007020193	A3	20071025		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
 MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,

SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
 US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 CA 2618335 A1 20070222 CA 2006-2618335 20060803
 EP 1928475 A2 20080611 EP 2006-778153 20060803
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
 JP 2009504704 T 20090205 JP 2008-526475 20060803
 US 20070042988 A1 20070222 US 2006-503558 20060811
 US 7608599 B2 20091027
 IN 2008CN00760 A 20090821 IN 2008-CN760 20080214
 CN 101287472 A 20081015 CN 2006-80038238 20080414
 PRAI US 2005-708726P P 20050815
 WO 2006-EP65021 W 20060803

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 146:252063; MARPAT 146:252063

GI



AB The invention provides novel nucleoside phosphoramidates I, wherein R and R2 are independently hydrogen, alkyl, alkylamine, hydroxyalkyl, CH₂SH, (CH₂)₂S(O)pMe, (CH₂)₃NHC(=NH)NH₂, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, aryl and aryl-alkyl; R and R2 together are (CH₂)_n; R1 is hydrogen, haloalkyl, aryl wherein said aryl is Ph or naphthyl optionally substituted with one to three substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halogen, haloalkyl, amine, acylamino, aminosulfonylalkyl, sulfonylamine, acyl, nitro and cyano; R3 is hydrogen, alkyl, haloalkyl, aryl aryl-alkyl wherein said aryl is phenyl; R4 is hydrogen, alkyl; R5 is azide, C.tplbond.CH or -(Z)-CH=CHCl; R6 is nucleobase; R7 is H, alkoxy; R8 is H, acyl; R9 is H, alkoxy; p = 0-2; n = 3-5 were prepared and are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases. Thus, (S)-2-[[[2R,3S,4R,5R)-2-azido-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-ylmethoxy]phenoxyphosphorylamino]propionic acid iso-Pr ester was prepared and evaluated as antiviral agent for the treatment of diseases mediated by Hepatitis C Virus and showed inhibition of luciferase (IC₅₀ = 0.864 μM).

IT	926308-35-2P	926308-38-5P	926308-39-6P
	926308-40-9P	926308-42-1P	926308-43-2P
	926308-49-8P	926308-50-1P	926308-56-7P
	926308-58-9P	926308-59-0P	926308-61-4P
	926308-63-6P	926308-66-9P	926308-67-0P
	926308-69-2P	926308-70-5P	926308-71-6P
	926308-72-7P	926308-77-2P	926308-78-3P
	926308-82-9P	926308-83-0P	926308-84-1P
	926308-87-4P	926308-88-5P	926308-91-0P
	926308-93-2P	926308-95-4P	926308-98-7P
	926308-99-8P	926309-01-5P	926309-03-7P
	926309-04-8P	926309-05-9P	926309-06-0P
	926309-08-2P	926309-09-3P	926309-11-7P
	926309-12-8P	926309-15-1P	926309-18-4P
	926309-19-5P	926309-21-9P	926309-22-0P
	926309-24-2P	926309-29-7P	926309-30-0P
	926309-31-1P	926309-33-3P	926309-35-5P

926309-36-6P 926309-38-8P 926309-40-2P
 926309-42-4P 926309-43-5P 926309-45-7P
 926309-46-8P 926309-47-9P 926309-48-0P
 926309-52-6P 926309-56-0P 926309-64-0P
 926309-67-3P 926309-71-9P 926309-72-0P
 926309-73-1P 926309-74-2P 926309-75-3P
 926309-76-4P 926309-77-5P 926309-80-0P
 926309-82-2P 926309-83-3P 926309-85-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino acid-containing nucleotide phosphoramidates as antiviral agents)

RN 926308-35-2 CAPLUS

CN L-Phenylalanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 926308-38-5 CAPLUS

CN L-Phenylalanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 926308-39-6 CAPLUS

CN L-Phenylalanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 926308-40-9 CAPLUS


CN L-Phenylalanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-42-1 CAPLUS
CN Cytidine, 4'-C-azido-, 5'-(phenyl N-[1,1-dimethyl-2-oxo-2-(phenylmethoxy)ethyl]phosphoramidate) (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-43-2 CAPLUS
CN Uridine, 4'-C-azido-, 5'-(phenyl N-[1,1-dimethyl-2-oxo-2-(phenylmethoxy)ethyl]phosphoramidate) (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-49-8 CAPLUS
CN Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-2-methyl-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-50-1 CAPLUS
CN Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-2-methyl-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-56-7 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, 1-methylpropyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-58-9 CAPLUS
 CN D-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-59-0 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-61-4 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-63-6 CAPLUS
 CN Glycine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-66-9 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-67-0 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-69-2 CAPLUS
 CN L-Alanine, N-(4'-C-ethynyl-P-phenyl-5'-uridylyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-70-5 CAPLUS
 CN 2,4(1H,3H)-Pyrimidinedione, 1-[5,6-dideoxy-4-C-(3-oxido-6-oxo-3-phenoxy-8-phenyl-2,7-dioxa-4-aza-3-phosphoacetyl-1-yl)-alpha-L-lyxo-hex-5-ynofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-71-6 CAPLUS
 CN L-Alanine, N-(4'-C-ethynyl-P-phenyl-5'-uridylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-72-7 CAPLUS
 CN D-Alanine, N-(4'-C-ethynyl-P-phenyl-5'-uridylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-77-2 CAPLUS
 CN L-Phenylalanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-78-3 CAPLUS
 CN Cytidine, 4'-C-azido-, 5'-[phenyl N-[1-(phenylmethoxy)carbonyl]cyclopentyl]phosphoramidate] (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-82-9 CAPLUS
 CN Uridine, 4'-C-azido-, 5'-[phenyl N-[1-(phenylmethoxy)carbonyl]cyclopentyl]phosphoramidate] (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-83-0 CAPLUS
 CN Uridine, 4'-C-azido-, 5'-[hydrogen N-[1-(ethoxycarbonyl)cyclopentyl]cyclopentyl]phosphoramidate] (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-84-1 CAPLUS
 CN Uridine, 4'-C-azido-, 5'-[phenyl N-[1-[(1-methylethoxy)carbonyl]cyclopentyl]cyclopentyl]phosphoramidate] (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-87-4 CAPLUS
 CN L-Leucine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-88-5 CAPLUS
CN L-Leucine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-91-0 CAPLUS
CN L-Leucine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-93-2 CAPLUS
CN L-Leucine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-95-4 CAPLUS
CN L-Leucine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-98-7 CAPLUS
 CN L-Valine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926308-99-8 CAPLUS
 CN L-Valine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-01-5 CAPLUS
 CN L-Isoleucine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-03-7 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-04-8 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-05-9 CAPLUS
 CN D-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-06-0 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-08-2 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-09-3 CAPLUS
 CN D-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-11-7 CAPLUS
 CN D-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-12-8 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-15-1 CAPLUS
 CN D-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, 1-methylpropyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-18-4 CAPLUS
 CN D-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, dodecyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-19-5 CAPLUS
 CN D-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, dodecyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-21-9 CAPLUS
 CN L-Methionine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-22-0 CAPLUS
 CN L-Methionine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-24-2 CAPLUS
 CN L-Glutamic acid, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, 1,5-diethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-29-7 CAPLUS
 CN L-Leucine, N-[4'-C-azido-P-(4-chlorophenyl)-5'-cytidylyl]-, ethyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-30-0 CAPLUS
 CN L-Leucine, N-[4'-C-azido-P-(4-chlorophenyl)-5'-uridylyl]-, ethyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-31-1 CAPLUS
 CN L-Alanine, N-[4'-C-azido-P-(4-chlorophenyl)-5'-uridylyl]-, phenylmethyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-33-3 CAPLUS
 CN D-Alanine, N-[4'-C-azido-P-(4-chlorophenyl)-5'-uridylyl]-, phenylmethyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-35-5 CAPLUS
 CN L-Leucine, N-[4'-C-azido-P-(3,4-dichlorophenyl)-5'-cytidylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-36-6 CAPLUS
 CN L-Leucine, N-[4'-C-azido-P-(3,4-dichlorophenyl)-5'-uridylyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 926309-38-8 CAPLUS
 CN D-Alanine, N-[4'-C-azido-P-(3,4-dichlorophenyl)-5'-uridylyl]-, phenylmethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 926309-40-2 CAPLUS
 CN L-Alanine, N-[4'-C-azido-P-(4-methylphenyl)-5'-uridylyl]-, ethyl ester

(CA INDEX NAME)


Absolute stereochemistry.



RN 926309-42-4 CAPLUS

CN L-Leucine, N-[4'-C-azido-P-(4-methylphenyl)-5'-cytidylyl]-, ethyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 926309-43-5 CAPLUS

CN L-Leucine, N-[4'-C-azido-P-(4-methylphenyl)-5'-uridylyl]-, ethyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 926309-45-7 CAPLUS


CN L-Leucine, N-[4'-C-azido-P-(4-methoxyphenyl)-5'-cytidylyl]-, ethyl ester
(CA INDEX NAME)

Absolute stereochemistry.




RN 926309-46-8 CAPLUS
 CN L-Alanine, N-[4'-C-azido-P-(4-methoxyphenyl)-5'-cytidylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-47-9 CAPLUS
 CN L-Leucine, N-[4'-C-azido-P-(4-methoxyphenyl)-5'-uridyllyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-48-0 CAPLUS
 CN L-Alanine, N-[4'-C-azido-P-(4-methoxyphenyl)-5'-uridyllyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 926309-52-6 CAPLUS
 CN L-Alanine, N-[4'-C-[(1Z)-2-chloroethenyl]-P-phenyl-5'-uridyllyl]-, phenylmethyl ester (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



10/560, 887


RN 926309-56-0 CAPLUS
CN L-Alanine, N-[4'-C-azido-P-(1-bromo-2-naphthalenyl)-5'-uridylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-64-0 CAPLUS
CN L-Aspartic acid, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, 1,4-diethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 926309-67-3 CAPLUS
CN D-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-71-9 CAPLUS
CN L-Phenylalanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, ethyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 926308-35-2
CMF C26 H30 N7 O9 P

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 926309-72-0 CAPLUS
CN L-Phenylalanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, ethyl ester, formate (1:1) (CA INDEX NAME)

CM 1

CRN 926308-35-2
CMF C26 H30 N7 O9 P


Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2RN 926309-73-1 CAPLUS
CN L-Glutamic acid, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, 1,5-diethyl ester (CA INDEX NAME)


Absolute stereochemistry.



10/560, 887


RN 926309-74-2 CAPLUS
CN D-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, butyl ester (CA INDEX
NAME)

Absolute stereochemistry.




RN 926309-75-3 CAPLUS
CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, butyl ester (CA INDEX
NAME)

Absolute stereochemistry.




RN 926309-76-4 CAPLUS
CN D-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, butyl ester (CA INDEX
NAME)

Absolute stereochemistry.



RN 926309-77-5 CAPLUS
CN L-Alanine, N-[4'-C-azido-P-(4-methylphenyl)-5'-cytidylyl]-, butyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 926309-80-0 CAPLUS
CN L-Alanine, N-(4'-C-azido-P-1-naphthalenyl-5'-uridylyl)-,
2,2,2-trifluoroethyl ester (CA INDEX NAME)


Absolute stereochemistry.

McIntosh




RN 926309-82-2 CAPLUS
 CN L-Alanine, N-[4'-C-azido-2',3'-bis-O-(1-oxopentyl)-P-phenyl-5'-cytidylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 926309-83-3 CAPLUS
 CN Cytidine, 4'-C-azido-, 5'-[phenyl N-[1-[(1-methylethoxy)carbonyl]cyclopentyl]phosphoramidate] (CA INDEX NAME)

Absolute stereochemistry.



RN 926309-85-5 CAPLUS
 CN L-Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




IT 926308-44-3P 926308-46-5P 926308-74-9P
 926308-79-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of amino acid-containing nucleotide phosphoramides as antiviral agents)

RN 926308-44-3 CAPLUS

CN Alanine, N-(4'-C-azido-P-phenyl-5'-cytidylyl)-2-methyl-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 926308-46-5 CAPLUS

CN Alanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-2-methyl-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 926308-74-9 CAPLUS

CN L-Phenylalanine, N-(4'-C-azido-P-phenyl-5'-uridylyl)-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 926308-79-4 CAPLUS

CN Cytidine, 4'-C-azido-, 5'-[phenyl N-[1-(ethoxycarbonyl)cyclopentyl]phosphoramidate] (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L4 ANSWER 18 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2006:1206158 CAPLUS

DN 145:500034

TI Phosphoramidate prodrugs for treatment of viral infection

IN Gunic, Esmir; Chow, Suetying; Rong, Frank

PA Valeant Research & Development, USA

SO PCT Int. Appl., 147pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006121820	A1	20061116	WO 2006-US17314	20060505
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2005-678636P	P	20050505		
	US 2005-748034P	P	20051206		
OS	MARPAT 145:500034				
AB	The invention concerns 2'-Me ribonucleotide phosphoramides which are neutral prodrugs which are converted in vivo to 2'- Me ribonucleotide triphosphates. These compds. are useful in the treatment of viral infection. Of particular interest are prodrugs of a methylsulfonylhydrazinyl purine 2'-Me nucleotide triphosphate: 2'-methyl-N6-alkyl-N6- (N-methylsulfonamide) ATP and its 2-amino derivative				
IT	1075703-77-3	1075705-71-3	1075716-43-6		
	1075716-44-7	1075716-45-8	1075716-46-9		
	1075716-47-0	1075716-48-1	1075716-49-2		
	1075716-50-5	1075716-53-8	1075716-55-0		
	1075716-56-1	1075716-57-2	1075716-64-1		
	1075716-65-2	1075716-70-9	1075717-09-7		
	1075717-12-2	1075720-37-4	1075721-70-8		
	1075721-76-4	1075721-77-5	1075721-80-0		
	1075721-82-2	1075721-85-5	1075721-86-6		
	1075721-94-6	1075737-66-4	1075738-82-7		
RL:	PRPH (Prophetic) (Phosphoramidate prodrugs for treatment of viral infection)				
RN	1075703-77-3	CAPLUS			
CN	INDEX NAME NOT YET ASSIGNED				

Absolute stereochemistry.


RN 1075705-71-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075716-43-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075716-44-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1075716-45-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



10/560, 887


RN 1075716-46-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075716-47-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075716-48-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075716-49-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075716-50-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075716-53-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075716-55-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075716-56-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075716-57-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075716-64-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075716-65-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075716-70-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075717-09-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1075717-12-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



10/560, 887


RN 1075720-37-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075721-70-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075721-76-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075721-77-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075721-80-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075721-82-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1075721-85-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



10/560, 887


RN 1075721-86-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075721-94-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075737-66-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1075738-82-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



IT 914912-07-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (phosphoramidate prodrugs for treatment of viral infection)
 RN 914912-07-5 CAPLUS
 CN Alanine, N-[(4-chlorophenoxy)hydroxymethylphosphinyl]-2-methyl-, methyl ester,
 5'-ester with 2'-C-methylcytidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2005:1315892 CAPLUS
 DN 144:163499
 TI Novel Potential Anticancer Naphthyl Phosphoramides of BVdU: Separation of Diastereoisomers and Assignment of the Absolute Configuration of the Phosphorus Center
 AU Congiatu, Costantino; Brancale, Andrea; Mason, Malcolm D.; Jiang, Wen G.; McGuigan, Christopher
 CS Welsh School of Pharmacy, Cardiff University, Cardiff, CF10 3XF, UK
 SO Journal of Medicinal Chemistry (2006), 49(2), 452-455
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 144:163499
 AB We have previously reported our SAR optimization of the anticancer agent thymectacin. Tuning of the parent ProTide structure initially involved the amino acid and, subsequently, the aromatic masking group on the phosphate moiety. Herein, derivs. bearing the combined modifications are reported and biol. evaluation is described. Moreover, separation of the diastereoisomeric final product mixture shows a different cytostatic activity for the two diastereoisomers. Through computational and NMR studies, the absolute stereochem. of the phosphorus center of the two diastereoisomers has been suggested.
 IT 874362-33-1P 874362-34-2P
 RL: PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (novel potential anticancer naphthyl phosphoramides of BVdU: separation of diastereoisomers and assignment of absolute configuration of phosphorus


center)
RN 874362-33-1 CAPLUS
CN D-Alanine, N-[{P(R)}]-5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 874362-34-2 CAPLUS
CN D-Alanine, N-[{P(S)}]-5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




IT 874362-00-2P 874362-01-3P 874362-02-4P
874362-03-5P 874362-04-6P 874362-05-7P
874362-06-8P 874362-07-9P 874362-08-0P
874362-09-1P 874362-10-4P 874362-11-5P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel potential anticancer naphthyl phosphoramidates of BVdU: separation of diastereoisomers and assignment of absolute configuration of phosphorus center)


RN 874362-00-2 CAPLUS
CN Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 874362-01-3 CAPLUS
 CN Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl]-2-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 874362-02-4 CAPLUS
 CN L-Isoleucine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 874362-03-5 CAPLUS
 CN L-Isoleucine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 874362-04-6 CAPLUS

CN Glycine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl]-2-phenyl-, methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 874362-05-7 CAPLUS

CN L-Valine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 874362-06-8 CAPLUS


CN L-Valine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 874362-07-9 CAPLUS
CN L-Phenylalanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 874362-08-0 CAPLUS
CN L-Phenylalanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 874362-09-1 CAPLUS


CN D-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 874362-10-4 CAPLUS
CN L-Methionine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 874362-11-5 CAPLUS
CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




OSC.G 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
 RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2005:1290072 CAPLUS
 DN 144:46998
 TI The x-ray crystal structure of BRCA1 tandem BRCT repeat and BACH1 phosphopeptide complex and methods and compositions for antitumor drug design
 IN Yaffe, Michael B.; Clapperton, Julie A.; Manke, Isaac A.; Lowery, Drew M.; Ho, Timmy; Haire, Lesley F.; Smerdon, Stephen J.
 PA Massachusetts Institute of Technology, USA
 SO PCT Int. Appl., 360 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115454	A2	20051208	WO 2005-US15981	20050509
WO 2005115454	A3	20071115		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA			
AU 2005247346	A1	20051208	AU 2005-247346	20050509
CA 2569003	A1	20051208	CA 2005-2569003	20050509
EP 1773389	A2	20070418	EP 2005-780060	20050509
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
JP 2007537164	T	20071220	JP 2007-511664	20050509
US 20090143997	A1	20090604	US 2008-229740	20080826
PRAI US 2004-569131P	P	20040507		
US 2005-126022	B3	20050509		
WO 2005-US15981	W	20050509		
AB	The present invention relates to compds. (e.g., peptidomimetics and non-peptides) that treat, prevent or stabilize cellular proliferative disorders and methods of treating, preventing, or stabilizing such disorders. The invention also provides three-dimensional structures of a BRCT domain-BACH1 phosphopeptide complex.			
IT 232925-18-7, Thymectacin				
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(x-ray crystal structure of BRCA1 tandem BRCT repeat and BACH1 phosphopeptide complex and methods and compns. for antitumor drug design)				
RN 232925-18-7 CAPLUS				
CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)				

Absolute stereochemistry.
 Double bond geometry as shown.



L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2005:1151332 CAPLUS

DN 145:271969

TI Naphthyl phosphoramidate derivatives of BVdU as potential anticancer agents: Design, synthesis and biological evaluation

AU Congiatu, C.; McGuigan, C.; Jiang, W. G.; Davies, G.; Mason, M. D.
 CS Welsh School of Pharmacy, Cardiff University, Cardiff, UK

SO Nucleosides, Nucleotides & Nucleic Acids (2005), 24(5-7), 485-489
 CODEN: NNNAFY; ISSN: 1525-7770


PB Taylor & Francis, Inc.

DT Journal

LA English

OS CASREACT 145:271969

GI



AB The phosphoramidate technol. has been recently applied to BVdU, leading to NB1011 (NewBiotics Inc., California), a novel potential anticancer compound recently entered into phase 2 of the clin. trials for colon cancer. A new series of derivs. containing naphthol and amino acid moieties as aryl masking group on the phosphate moiety, e.g. I, which has shown a significant increase in anticancer activity in preliminary biol. evaluations, is reported.

IT 232925-18-7, NB 1011


RL: PAC (Pharmacological activity); BIOL (Biological study)
 (preparation of naphthyl phosphoramidate derivs. of bromovinyl deoxyuridine (BVdU) as anticancer agents)

RN 232925-18-7 CAPLUS

CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 906670-25-5P 906670-26-6P 906670-27-7P
 906670-28-8P 906670-29-9P 906670-30-2P
 906670-31-3P 906670-32-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation of naphthyl phosphoramidate derivs. of bromovinyl deoxyuridine
 (BVdU) as anticancer agents)

RN 906670-25-5 CAPLUS

CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-
 uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 906670-26-6 CAPLUS

CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-
 uridylyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 906670-27-7 CAPLUS


CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 906670-28-8 CAPLUS
CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-2-naphthalenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 906670-29-9 CAPLUS
CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-2-naphthalenyl-5'-uridylyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 906670-30-2 CAPLUS
CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-2-naphthalenyl-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 906670-31-3 CAPLUS

CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-P-(4-chloro-1-naphthalenyl)-2'-deoxy-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 906670-32-4 CAPLUS

CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-(4-methoxy-1-naphthalenyl)-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 874362-02-4P 874362-03-5P 874362-04-6P
874362-05-7P 874362-06-8P 874362-07-9P

874362-08-0P 874362-09-1P 874362-10-4P
 874362-11-5P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of naphthyl phosphoramidate derivs. of bromovinyl deoxyuridine
 (BVdU) as anticancer agents)

RN 874362-02-4 CAPLUS

CN L-Isoleucine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-
 uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 874362-03-5 CAPLUS

CN L-Isoleucine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-
 uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 874362-04-6 CAPLUS

CN Glycine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl]-
 2-phenyl-, methyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 874362-05-7 CAPLUS
 CN L-Valine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 874362-06-8 CAPLUS
 CN L-Valine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 874362-07-9 CAPLUS
 CN L-Phenylalanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 874362-08-0 CAPLUS

CN L-Phenylalanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 874362-09-1 CAPLUS

CN D-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 874362-10-4 CAPLUS


CN L-Methionine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 874362-11-5 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-1-naphthalenyl-5'-uridyllyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
 RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2005:409543 CAPLUS
 DN 142:457053
 TI Human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy
 IN Lacasse, Eric; McManus, Daniel
 PA Aegea Therapeutics, Inc., Can.
 SO PCT Int. Appl., 112 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI WO 2005042558 A1 20050512 WO 2004-CA1902 20041029
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 20050148535 A1 20050707 US 2004-975974 20041028
 CA 2542904 A1 20050512 CA 2004-2542904 20041029
 EP 1682565 A1 20060726 EP 2004-789809 20041029
 R: DE, FR, GB
 JP 2007510408 T 20070426 JP 2006-537024 20041029
 PRAI US 2003-516192P P 20031030
 WO 2004-CA1902 W 20041029

AB The invention provides nucleobase oligomers and oligonucleotide duplexes that inhibit expression of an IAP (inhibitor of apoptosis protein), and methods for using them to induce apoptosis in a cell. Specifically, the invention provides nucleic acid sequences for siRNAs and shRNAs that target human XIAP, HIAP-1 or HIAP-2 genes. The nucleobase oligomers and oligomer complexes of the present invention may also be used to form pharmaceutical compns. The invention also features methods for enhancing apoptosis in a cell by administering a nucleobase oligomer or oligomer complex of the invention in combination with a chemotherapeutic or chemosensitizing agent. RNAi sequences and vectors producing shRNA (short hairpin RNA) were transfected into HeLa cells and evaluated for their effect on XIAP, cIAP-1, or cIAP-2 protein levels. XIAP protein could also be reduced by RNAi clones in transfected breast cancer cell line MDA-MB-231. In addition, cell survival was reduced in XIAP RNAi transfected breast cancer cell line after the transfected cells were treated with TRAIL (tumor necrosis factor-related apoptosis inducing ligand).
 IT 232925-18-7, Thymectacin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy)
 RN 232925-18-7 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2005:409357 CAPLUS
 DN 142:457052
 TI Sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with a chemotherapeutic agent
 IN Lacasse, Eric; McManus, Daniel; Durkin, Jon P.
 PA Aegea Therapeutics, Inc., Can.
 SO PCT Int. Appl., 285 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 2005042030	A1	20050512	WO 2004-CA1900	20041029
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US	20050119217	A1	20050602	US 2004-975790	20041028
AU	2004284855	A1	20050512	AU 2004-284855	20041029
CA	2542884	A1	20050512	CA 2004-2542884	20041029
EP	1691842	A1	20060823	EP 2004-789807	20041029
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR	2004015779	A	20061226	BR 2004-15779	20041029
CN	1901939	A	20070124	CN 2004-80039601	20041029
JP	2007509861	T	20070419	JP 2006-537023	20041029
ZA	2006003399	A	20070926	ZA 2006-3399	20041029
NZ	547191	A	20090828	NZ 2004-547191	20041029
RU	2376018	C2	20091220	RU 2006-117024	20041029
SG	157422	A1	20091229	SG 2009-7918	20041029
MX	2006004920	A	20070216	MX 2006-4920	20060502
IN	2006MN00614	A	20070420	IN 2006-MN614	20060526
NO	2006002420	A	20060731	NO 2006-2420	20060529
KR	2006127393	A	20061212	KR 2006-710619	20060530
PRAI	US 2003-516263P	P	20031030		
	WO 2004-CA1900	W	20041029		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention claims the use of an antisense oligomer to human XIAP, IAP-1 or IAP-2 genes and a chemotherapeutic agent, and compns. and kits thereof, for the treatment of proliferative diseases. The invention further claims sequences for nucleobase oligomers that are antisense IAP (inhibitor of apoptosis protein) oligomers. The antisense IAP nucleobase oligomers specifically hybridize with polynucleotides encoding an IAP and reduce the amount of an IAP protein produced in a cell. Thus by reducing the IAP protein, the invention provides methods for inducing cancer cells to undergo apoptosis and for overriding anti-apoptotic signals in cancer cells. As an example of the invention, mice with s.c. H460 human lung carcinoma xenografts were injected intratumorally with XIAP antisense mixed-base 2'-O-Me RNA oligonucleotides (C5 and/or G4) and the drug vinorelbine. At the end of the 24 d treatment period, the mean relative tumor growth was reduced .apprx.70% in treated mice. The inhibition of tumor growth was correlated with down-regulation of human XIAP protein expression and an increased number of dead cells. The mice did not show any signs of cytotoxicity such as body weight loss.

IT 232925-18-7, Thymectacin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sequences of antisense IAP (inhibitor of apoptosis protein) oligomers
and their use for treatment of proliferative diseases with
chemotherapeutic agent)

RN 232925-18-7 CAPLUS

CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
 RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2005:288972 CAPLUS
 DN 143:7925
 TI Anti-cancer ProTides: tuning the activity of BVDU phosphoramidates related to thymectacin
 AU McGuigan, Christopher; Thiery, Jean-Christophe; Daverio, Felice; Jiang, Wen G.; Davies, Gaynor; Mason, Malcolm
 CS Welsh School of Pharmacy, Cardiff University, Cardiff, CF10 3XF, UK
 SO Bioorganic & Medicinal Chemistry (2005), 13(9), 3219-3227
 CODEN: BMECEP; ISSN: 0968-0896
 PB Elsevier Ltd.
 DT Journal
 LA English
 OS CASREACT 143:7925
 AB Based on our wide ranging knowledge of phosphoramidate ProTides as anti-viral agents we have tuned the lead anti-cancer agent thymectacin in the ester and amino acid regions and revealed a substantial enhancement in in vitro potency vs. colon and prostate cancer cell lines. Twelve analogs have been reported, with yields of 29-78%. The compds. are fully characterized and data clearly reveal the presence of two phosphate diastereoisomers, as expected, in roughly equi-molar proportions. The compds. were evaluated in tissue culture vs. three different tumor cell lines, using thymectacin as the control. It is notable that minor structural modification of the parent Ph methoxylaninyl structure of thymectacin leads to significant enhancements in potency. In particular, replacement of the Me ester moiety in the lead by a benzyl ester gave a 175-fold boost in potency vs. colon cancer HT115. This derivative emerges as a low micromolar inhibitor of HT115 cells and a new lead for further optimization.
 IT 232925-18-7P 436097-54-0P 436097-55-1P
 535958-46-4P 840505-89-7P 840505-93-3P
 840505-98-8P 840505-99-9P 840506-00-5P
 840506-09-4P 840506-10-7P 840506-11-8P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
 BIOL (Biological study); PREP (Preparation)
 (preparation of thymectacin analogs as potential anti-cancer agents)
 RN 232925-18-7 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 436097-54-0 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 436097-55-1 CAPLUS
 CN Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 535958-46-4 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840505-89-7 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-(4-fluorophenyl)-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840505-93-3 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-(4-nitrophenyl)-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 840505-98-8 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-P-(4-chlorophenyl)-2'-deoxy-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840505-99-9 CAPLUS

CN Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridyllyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-00-5 CAPLUS

CN Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridyllyl]-2-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-09-4 CAPLUS

CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[phenyl[1-(methoxycarbonyl)cyclopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-10-7 CAPLUS

CN Uridine, 5-[{(1E)-2-bromoethenyl}-2'-deoxy-, 5'-[phenyl[1-(ethoxycarbonyl)cyclopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-11-8 CAPLUS

CN Uridine, 5-[{(1E)-2-bromoethenyl}-2'-deoxy-, 5'-[phenyl[1-(phenylmethoxy)carbonyl]cyclopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



OSC.G 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2005:283298 CAPLUS

DN 142:349042

TI Combinations of chlorpromazine compounds and antiproliferative drugs for the treatment of neoplasms

IN Lee, Margaret S.; Nichols, James M.; Zhang, Yanzhen; Keith, Curtis

PA Combinatorix, Incorporated, USA

SO PCT Int. Appl., 65 pp.


CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005027842	A2	20050331	WO 2004-US30368	20040916
	WO 2005027842	A3	20051222		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NT, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004273910	A1	20050331	AU 2004-273910	20040916
	CA 2538570	A1	20050331	CA 2004-2538570	20040916
	EP 1670477	A2	20060621	EP 2004-788798	20040916
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004014568	A	20061107	BR 2004-14568	20040916
	CN 1878556	A	20061213	CN 2004-80033294	20040916
	JP 2007505914	T	20070315	JP 2006-527024	20040916
	MX 2006003066	A	20060620	MX 2006-3066	20060317
	NO 2006001325	A	20060606	NO 2006-1325	20060323
	KR 2007012618	A	20070126	KR 2006-707244	20060414
PRAI	US 2003-504310P	P	20030918		
	WO 2004-US30368	W	20040916		
OS	MARPAT 142:349042				
AB	The invention discloses a method for treating a patient having a cancer or other neoplasm by administering chlorpromazine or a chlorpromazine analog and an antiproliferative agent simultaneously or within 14 days of each other in amts. sufficient to treat the patient.				
IT	232925-18-7, Thymectacin RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (chlorpromazine compound-antiproliferative drug antitumor combination)				
RN	232925-18-7 CAPLUS				
CN	L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)				

Absolute stereochemistry.

Double bond geometry as shown.



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L4 ANSWER 26 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2005:120951 CAPLUS
 DN 142:219498
 TI Preparation of amino acid-containing nucleotide phosphoramidates as antitumor agents
 IN McGuigan, Christopher
 PA University College Cardiff Consultants Limited, UK
 SO PCT Int. Appl., 124 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012327	A2	20050210	WO 2004-GB3148	20040720
	WO 2005012327	A3	20050421		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NT, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004261455	A1	20050210	AU 2004-261455	20040720
	CA 2518115	A1	20050210	CA 2004-2518115	20040720
	EP 1646639	A2	20060419	EP 2004-743483	20040720
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	JP 2006528162	T	20061214	JP 2006-520890	20040720
	NZ 541974	A	20090331	NZ 2004-541974	20040720
	NO 2005003993	A	20051102	NO 2005-3993	20050826
	MX 2005012606	A	20060208	MX 2005-12606	20051122
	US 20060142238	A1	20060629	US 2005-560887	20051215
PRAI	GB 2003-17009	A	20030721		
	WO 2004-GB3148	A	20040720		
OS	CASREACT 142:219498; MARPAT 142:219498				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Amino acid-containing nucleotide phosphoramidates I, wherein R is alkyl, aryl, alkylaryl; R1 and R2 are independently H, alkyl, alkylaryl; R1 and R2 together form an alkylene chain so as to provide, together with the C atom to which they are attached, a cyclic system; Q is -O- and -CH-; X and Y are independently H, F, Cl, Br, I, OH and Me; Ar is a monocyclic aromatic ring moiety or a fused bicyclic aromatic ring moiety, either of which said ring moieties is carbocyclic or heterocyclic and is optionally substituted; Z is H, alkyl and halogen, were prepared and used in the treatment of cancer. The base moieties of, for example, each of deoxyuridine, cytarabine, gemcitabine and cytidine may be substituted at the 5-position. The phosphoramidate moiety has attached to the P atom an aryl-O moiety and an α -amino acid moiety. The α -amino acid moiety may correspond to or be derived from either a naturally occurring or a non-naturally occurring amino acid. Thus, title II was prepared and tested as antitumor agent. The activity of compds. embodying the present invention, and of some comparative compds., with respect to human breast cancer cell line MDA MB231, human colon cancer cell line HT1 15 and human prostate cancer cell line PC-3, is reported.

IT	232925-18-7P	436097-54-0P	436097-55-1P
	436097-56-2P	535958-46-4P	535958-47-5P
	535958-53-3P	535958-60-2P	840505-87-5P
	840505-88-6P	840505-89-7P	840505-91-1P
	840505-92-2P	840505-93-3P	840505-94-4P
	840505-95-5P	840505-96-6P	840505-97-7P
	840505-98-8P	840505-99-9P	840506-00-5P
	840506-01-6P	840506-02-7P	840506-03-8P
	840506-04-9P	840506-05-0P	840506-06-1P
	840506-08-3P	840506-09-4P	840506-10-7P
	840506-11-8P	840506-12-9P	840506-13-0P
	840506-14-1P	840506-15-2P	840506-16-3P
	840506-17-4P	840506-18-5P	840506-19-6P
	840506-20-9P	840506-21-0P	840506-22-1P
	840506-23-2P	840506-24-3P	840506-25-4P
	840506-26-5P	840506-27-6P	840506-28-7P
	840506-29-8P	840506-31-2P	840506-32-3P

840506-69-6P 840506-70-9P 840506-73-2P
 840506-74-3P 840506-75-4P 840506-76-5P
 840506-77-6P 840506-78-7P 840506-79-8P
 840506-80-1P 840506-81-2P 840506-82-3P
 840506-83-4P 840506-85-6P 840506-86-7P
 840506-87-8P 840506-88-9P 840506-89-0P
 840506-90-3P 840506-91-4P 840506-92-5P
 840506-93-6P 840506-94-7P 840506-95-8P
 840506-96-9P 840506-97-0P 840506-98-1P
 840506-99-2P 840507-00-8P 840507-01-9P
 840507-02-0P 840507-03-1P 840507-04-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of amino acid-containing nucleotide phosphoramides as antitumor agents)

RN 232925-18-7 CAPLUS

CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridyllyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 436097-54-0 CAPLUS

CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridyllyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 436097-55-1 CAPLUS

CN Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridyllyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 436097-56-2 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-P-(4-chlorophenyl)-2'-deoxy-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 535958-46-4 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 535958-47-5 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 535958-53-3 CAPLUS
 CN L-Tryptophan, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 535958-60-2 CAPLUS
 CN Glycine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840505-87-5 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-(4-fluorophenyl)-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840505-88-6 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-(4-fluorophenyl)-5'-uridylyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840505-89-7 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-(4-fluorophenyl)-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840505-91-1 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-(4-nitrophenyl)-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840505-92-2 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-(4-nitrophenyl)-5'-uridylyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840505-93-3 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-(4-nitrophenyl)-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 840505-94-4 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-[4-(trifluoromethyl)phenyl]-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840505-95-5 CAPLUS

CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-[4-(trifluoromethyl)phenyl]-5'-uridylyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840505-96-6 CAPLUS

CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-[4-(trifluoromethyl)phenyl]-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840505-97-7 CAPLUS

CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-P-(4-chlorophenyl)-2'-deoxy-5'-uridylyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 840505-98-8 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-P-(4-chlorophenyl)-2'-deoxy-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840505-99-9 CAPLUS
 CN Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840506-00-5 CAPLUS
 CN Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-2-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840506-01-6 CAPLUS
 CN Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-(4-nitrophenyl)-5'-uridylyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840506-02-7 CAPLUS
 CN Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-(4-nitrophenyl)-5'-uridylyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840506-03-8 CAPLUS
 CN Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-(4-nitrophenyl)-5'-uridylyl]-2-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840506-04-9 CAPLUS
CN Alanine, N-[5-[(1E)-2-bromoethenyl]-P-(4-chlorophenyl)-2'-deoxy-5'-uridylyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 840506-05-0 CAPLUS
CN Alanine, N-[5-[(1E)-2-bromoethenyl]-P-(4-chlorophenyl)-2'-deoxy-5'-uridylyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840506-06-1 CAPLUS
CN Alanine, N-[5-[(1E)-2-bromoethenyl]-P-(4-chlorophenyl)-2'-deoxy-5'-uridylyl]-2-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 840506-08-3 CAPLUS

CN Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-[4-(trifluoromethyl)phenyl]-5'-uridylyl]-2-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-09-4 CAPLUS

CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[phenyl[1-(methoxycarbonyl)cyclopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-10-7 CAPLUS

CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[phenyl[1-(ethoxycarbonyl)cyclopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-11-8 CAPLUS

CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[phenyl [1-[(phenylmethoxy)carbonyl]cyclopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-12-9 CAPLUS

CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[4-nitrophenyl [1-(methoxycarbonyl)cyclopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-13-0 CAPLUS

CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[4-nitrophenyl [1-(ethoxycarbonyl)cyclopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-14-1 CAPLUS

CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[4-nitrophenyl [1-[(phenylmethoxy)carbonyl]cyclopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-15-2 CAPLUS

CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[4-fluorophenyl [1-(methoxycarbonyl)cyclopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-16-3 CAPLUS

CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[4-fluorophenyl [1-(ethoxycarbonyl)cyclopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-17-4 CAPLUS

CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[4-fluorophenyl [1-[(phenylmethoxy)carbonyl]cyclopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-18-5 CAPLUS

CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[4-chlorophenyl [1-(methoxycarbonyl)cyclopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-19-6 CAPLUS

CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[4-chlorophenyl [1-(ethoxycarbonyl)cyclopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-20-9 CAPLUS

CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[4-chlorophenyl [1-[(phenylmethoxy)carbonyl]cyclopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-21-0 CAPLUS

CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[4-(trifluoromethyl)phenyl [1-(methoxycarbonyl)cyclopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-22-1 CAPLUS

CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[4-(trifluoromethyl)phenyl [1-(ethoxycarbonyl)cyclopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-23-2 CAPLUS

CN Uridine, 5-[{(1E)-2-bromoethenyl}-2'-deoxy-, 5'-(4-(trifluoromethyl)phenyl [1-[(phenylmethoxy)carbonyl]cyclopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-24-3 CAPLUS

CN L-Phenylalanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-25-4 CAPLUS

CN L-Leucine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-26-5 CAPLUS
 CN L-Leucine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridyllyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840506-27-6 CAPLUS
 CN L-Leucine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-(4-nitrophenyl)-5'-uridyllyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840506-28-7 CAPLUS
 CN L-Leucine, N-[5-[(1E)-2-bromoethenyl]-P-(4-chlorophenyl)-2'-deoxy-5'-uridyllyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840506-29-8 CAPLUS
 CN L-Alanine, N-(2'-deoxy-2',2'-difluoro-P-phenyl-5'-cytidylyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840506-31-2 CAPLUS
 CN L-Alanine, N-[P-(4-chlorophenyl)-2'-deoxy-2',2'-difluoro-5'-cytidylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 840506-32-3 CAPLUS
 CN Alanine, N-[P-(4-chlorophenyl)-2'-deoxy-2',2'-difluoro-5'-cytidylyl]-2-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 840506-69-6 CAPLUS


CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-P-(2-chlorophenyl)-2'-deoxy-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 840506-70-9 CAPLUS
CN Alanine, N-[5-[(1E)-2-bromoethenyl]-P-(2-chlorophenyl)-2'-deoxy-5'-uridylyl]-2-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 840506-73-2 CAPLUS
CN L-Phenylalanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840506-74-3 CAPLUS
CN D-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 840506-75-4 CAPLUS

CN D-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-76-5 CAPLUS

CN D-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-(4-nitrophenyl)-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-77-6 CAPLUS

CN Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-[4-(trifluoromethyl)phenyl]-5'-uridylyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-78-7 CAPLUS

CN Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-[4-(trifluoromethyl)phenyl]-5'-uridylyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-79-8 CAPLUS

CN Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-(4-fluorophenyl)-5'-uridylyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-80-1 CAPLUS

CN L-Phenylalanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-[4-(trifluoromethyl)phenyl]-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-81-2 CAPLUS

CN L-Leucine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-[4-(trifluoromethyl)phenyl]-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-82-3 CAPLUS

CN Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-(4-fluorophenyl)-5'-uridylyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-83-4 CAPLUS

CN Alanine, N-[2'-deoxy-5-[(1E)-3-methoxy-3-oxo-1-propenyl]-P-(4-nitrophenyl)-5'-uridylyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-85-6 CAPLUS

CN L-Methionine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-86-7 CAPLUS

CN L-Methionine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-87-8 CAPLUS

CN L-Isoleucine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-88-9 CAPLUS

CN L-Isoleucine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-89-0 CAPLUS

CN Glycine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-90-3 CAPLUS

CN Glycine, N-[5-[(1E)-2-bromoethenyl]-P-(4-chlorophenyl)-2'-deoxy-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-91-4 CAPLUS

CN L-Valine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-[4-(trifluoromethyl)phenyl]phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-92-5 CAPLUS

CN L-Aspartic acid, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-93-6 CAPLUS

CN L-Glutamic acid, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 840506-94-7 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-P-(3-chlorophenyl)-2'-deoxy-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840506-95-8 CAPLUS
 CN Alanine, N-[5-[(1E)-2-bromoethenyl]-P-(3-chlorophenyl)-2'-deoxy-5'-uridylyl]-2-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840506-96-9 CAPLUS
 CN Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-(4-fluorophenyl)-5'-uridylyl]-2-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840506-97-0 CAPLUS
 CN L-Valine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridyllyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840506-98-1 CAPLUS
 CN L-Valine, N-[5-[(1E)-2-bromoethenyl]-P-(4-chlorophenyl)-2'-deoxy-5'-uridyllyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 840506-99-2 CAPLUS
 CN L-Valine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-(4-fluorophenyl)-5'-uridyllyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 840507-00-8 CAPLUS

CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[phenyl[2-oxo-1-phenyl-2-(phenylmethoxy)ethyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840507-01-9 CAPLUS

CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[4-chlorophenyl[2-oxo-1-phenyl-2-(phenylmethoxy)ethyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 840507-02-0 CAPLUS

CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[4-(trifluoromethyl)phenyl[2-oxo-1-phenyl-2-(phenylmethoxy)ethyl]phosphoramidate] (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 840507-03-1 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridyl]l-,
 2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 840507-04-2 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridyl]l-,
 1-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2003:927328 CAPLUS
 DN 140:35079
 TI Development of novel anticancer agent targeting thymidylate synthase
 AU Nakata, Rieko
 CS Dep. Human Life Environ., Nara Women's Univ., Japan
 SO Kagaku to Kogyo (Tokyo, Japan) (2003), 56(11), 1260
 CODEN: KAKTAF; ISSN: 0022-7684
 PB Nippon Kagakkai
 DT Journal; General Review


LA Japanese
 AB A review on the action mechanism and efficacy of NB 1011, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-dUMP.
 IT 232925-18-7, NB 1011
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (action mechanism and efficacy of antitumor drug NB 1011 targeting thymidylate synthase)
 RN 232925-18-7 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L4 ANSWER 28 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2003:543256 CAPLUS
 DN 140:35438
 TI NB1011 induces Ser15 phosphorylation of p53 and activates the G2/M checkpoint
 AU Dellinger, Ryan W.; Karjian, Patricia L.; Neuteboom, Saskia T. C.
 CS NewBiotics, Inc., San Diego, CA, USA
 SO Anti-Cancer Drugs (2003), 14(6), 449-455
 CODEN: ANTDEV; ISSN: 0959-4973
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 AB NB1011, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine, is a novel anti-cancer agent that selectively targets tumor cells expressing high levels of thymidylate synthase (TS), an enzyme required for DNA biosynthesis. NB1011 treatment of high-TS-expressing breast carcinoma cells (MCF7TDX) results in the induction of p53 and p21 protein levels, whereas no p53 or p21 induction is observed in the low-TS-expressing MCF7 tumor cells. Furthermore, MCF7TDX cells accumulate in the G2/M phase of the cell cycle in response to NB1011. In this study, the effect of NB1011 on the phosphorylation status of p53 was analyzed. We demonstrate that NB1011 treatment of various tumor cell lines expressing high TS results in the phosphorylation of p53 on Ser15, whereas this p53 phosphorylation is not observed in low-TS-expressing tumor cells. Also, we examined the role of several key cell cycle regulators in the growth inhibition observed in response to NB1011. Our results show that the mRNA and protein levels of the G2/M regulators cdc2, cyclin B1 and cdc25C are down-regulated in MCF7TDX cells, while unaffected in MCF7 cells. The mRNA and protein levels of 14-3-3 σ , also a direct transcriptional target of p53, are up-regulated in MCF7TDX cells following NB1011 treatment, while unchanged in MCF7 cells. Taken together, our data indicate that the growth inhibition caused by NB1011 in MCF7TDX cells is mediated through phosphorylation of p53 and activation of the G2/M checkpoint.
 IT 232925-18-7, NB1011
 RL: DMA (Drug mechanism of action); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (NB1011 induces Ser15 phosphorylation of p53 and activates the G2/M checkpoint)
 RN 232925-18-7 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2003:522871 CAPLUS
DN 139:242183
TI Kinetic properties of human thymidylate synthase, an anticancer drug target
AU Sergeeva, Oksana A.; Khambatta, H. Godrej; Cathers, Brian E.; Sergeeva, Maria V.
CS NewBiotics, Inc., San Diego, CA, 92121, USA
SO Biochemical and Biophysical Research Communications (2003), 307(2), 297-300
CODEN: BBRCA9; ISSN: 0006-291X
PB Elsevier Science
DT Journal
LA English
AB The kinetic parameters of human recombinant thymidylate synthase (hrTS) were determined with its natural substrate, dUMP, and with (E)-5-(2-bromovinyl)-2'-deoxyuridine monophosphate (BVdUMP), a nucleotide derivative believed to be the active species of the novel anticancer drug, NB 1011. NB 1011 is activated by hrTS and is selectively toxic to high TS-expressing tumor cells. Here, BVdUMP underwent hrTS-catalyzed SH group-dependent transformation and dUMP and BVdUMP acted as competitive hrTS substrates. The natural folate cofactor, 5,10-methylenetetrahydrofolate, inhibited the TS-catalyzed reaction with BVdUMP. The authors suggest that lower folate levels found in tumor cells favor TS-catalyzed BVdUMP transformation, which, in addition to higher levels of TS expression in tumor cells, contributes to the favorable therapeutic index of the drug, NB 1011.
IT 232925-18-7, NB 1011
RL: BSU (Biological study, unclassified); DMA (Drug mechanism of action); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reaction kinetics of human thymidylate synthase, with bromovinyl-dUMP, the active species of anticancer drug NB 1011)
RN 232925-18-7 CAPLUS
CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
 RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 30 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2003:515896 CAPLUS
 DN 140:64854
 TI Formulation development of a nucleotide phosphoramidate
 AU Natarajan, Gita; John, Elizabeth; Maniar, Manoj
 CS Formulation and Drug Delivery Group, BioSciences Division, SRI International, Menlo Park, CA, USA
 SO Pharmaceutical Technology (2003), 27(6), 66,68,70
 CODEN: PTHEC9; ISSN: 1543-2521
 PB Advanstar Communications, Inc.
 DT Journal
 LA English
 AB To develop a shelf-stable formulation of a cancer treatment under study, the authors evaluated 3 approaches: cosolvent systems, complexation, and micellar solubilization. Micellar solubilization with Polysorbate80 and cosurfactants was successful for developing a small-volume parenteral formulation for i.v. administration.
 IT 232925-18-7, NB1011
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (formulation development of nucleotide phosphoramidate)
 RN 232925-18-7 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



IT 232925-18-7DP, NB1011, complex with hydroxypropyl β-cyclodextrin
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (formulation development of nucleotide phosphoramidate)
 RN 232925-18-7 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 31 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2003:455061 CAPLUS
DN 139:7127
TI Preparation, cytotoxicity, antitumor, and antiinflammatory activities of nucleoside phosphoramidates
IN Shepard, H. Michael; Vaino, Andrew Rein; Lehsten, Danielle M.
PA USA
SO U.S. Pat. Appl. Publ., 58 pp., Cont.-in-part of U.S. Ser. No. 782,721.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20030109697	A1	20030612	US 2002-119927	20020409
	US 7462605	B2	20081209		
	EP 1167972	A2	20020102	EP 2001-120242	19990122
	EP 1167972	A3	20060524		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 6339151	B1	20020115	US 1999-235961	19990122
	JP 2001220397	A	20010814	JP 2000-339831	20001108
	JP 3265304	B2	20020311		
	US 20010034440	A1	20011025	US 2001-782721	20010212
	US 7601703	B2	20091013		
	US 20090069268	A1	20090312	US 2008-236323	20080923
PRAI	US 1998-72264P	P	19980123		
	US 1998-76950P	P	19980305		
	US 1998-108634P	P	19981116		
	US 1999-235961	A1	19990122		
	US 2001-782721	A2	20010212		
	EP 1999-904195	A3	19990122		
	JP 2000-528661	A3	19990122		
	US 2002-119927	A1	20020409		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 139:7127

GI



AB This invention provides compds., compns. and methods for treating cancer, infectious disease, an autoimmune disorder or an inflammatory condition. Therapeutic compds. useful in the methods of this invention are 5'-phosphoramidatyl, 1,5-substituted pyrimidine compds. I, wherein and pharmaceutically acceptable salts thereof. Thus, I (R1 = CH:CHBr, R2 = OH, R3 = H, R4 = Me, R5 = Et) was prepared and tested for its cytotoxicity, antitumor, and antiinflammatory activities. Expression of thymidylate synthase in human normal tissues. The thymidylate synthase (TS) expression level in normal human tissues was examined in order to estimate the systemic toxicity of the compound(s) activated by thymidylate synthase.

IT 322454-65-9P 436097-54-0P 535958-46-4P
 535958-47-5P 535958-48-6P 535958-49-7P
 535958-50-0P 535958-51-1P 535958-52-2P
 535958-53-3P 535958-54-4P 535958-55-5P
 535958-57-7P 535958-58-8P 535958-59-9P
 535958-60-2P 535958-61-3P 535958-62-4P
 535958-63-5P 535958-64-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation cytotoxicity antitumor and antiinflammatory activities of nucleoside phosphoramides)

RN 322454-65-9 CAPLUS

CN L-Alanine, N-[5-(2-bromoethenyl)-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 436097-54-0 CAPLUS

CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 535958-46-4 CAPLUS

CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 535958-47-5 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 535958-48-6 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 535958-49-7 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, cyclopropylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 535958-50-0 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, cyclohexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 535958-51-1 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, cycloheptyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 535958-52-2 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, cyclooctyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 535958-53-3 CAPLUS

CN L-Tryptophan, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 535958-54-4 CAPLUS

CN L-Tryptophan, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 535958-55-5 CAPLUS

CN L-Tryptophan, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, cyclooctyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 535958-57-7 CAPLUS
CN L-Valine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 535958-58-8 CAPLUS
CN L-Valine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 535958-59-9 CAPLUS
CN L-Valine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, cyclohexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 535958-60-2 CAPLUS
 CN Glycine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridyllyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 535958-61-3 CAPLUS
 CN L-Histidine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridyllyl]-, cyclohexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 535958-62-4 CAPLUS
 CN L-Leucine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridyllyl]-, cyclohexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 535958-63-5 CAPLUS
 CN L-Phenylalanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 535958-64-6 CAPLUS
 CN Uridine, 5-[(1E)-2-bromoethenyl]-2'-deoxy-, 5'-[phenyl [(1R)-5-methoxy-1-(methoxycarbonyl)-5-oxopentyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L4 ANSWER 32 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2003:302024 CAPLUS
 DN 139:117647
 TI Synthesis of serine/alanine conjugated 3',5'-TpT
 AU Qin, Zhi-Hui; Lin, Chang-Xue; Ju, Yong; Zhao, Yu-Fen
 CS Bioorganic Phosphorus Chemistry Laboratory, Department of Chemistry,
 School of Life Science and Engineering, Tsinghua University, Beijing,
 100084, Peop. Rep. China
 SO Nucleosides, Nucleotides & Nucleic Acids (2003), 22(1), 63-69

CODEN: NNNAFY; ISSN: 1525-7770

PB Marcel Dekker, Inc.

DT Journal

LA English

OS CASREACT 139:117647

AB Serine and alanine phosphoramidate conjugates of 3',5'-TpT were synthesized. The corresponding serine phosphoramidate possesses some unique properties due to the presence of the side chain hydroxyl group.


IT 548775-55-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of serine/alanine conjugated 3',5'-TpT via oxidative coupling of the dinucleotide phosphonate with L-amino acid Me esters)

RN 548775-55-9 CAPLUS

CN Thymidine, P-deoxy-P-[(1S)-1-(hydroxymethyl)-2-methoxy-2-oxoethyl]amino]thymidylyl-(3'→5')-, 3'-acetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 548775-54-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of serine/alanine conjugated 3',5'-TpT via oxidative coupling of the dinucleotide phosphonate with L-amino acid Me esters)

RN 548775-54-8 CAPLUS

CN Thymidine, P-deoxy-P-[(1S)-2-methoxy-1-methyl-2-oxoethyl]amino]thymidylyl-(3'→5')-, 3'-acetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 33 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2003:164629 CAPLUS

DN 139:190589


TI Cellular transformation of the investigational new anticancer drug NB1011, a phosphoramidate of 5-(2-bromovinyl)-2'-deoxyuridine, results in modification of cellular proteins not DNA

AU Sergeeva, Maria V.; Cathers, Brian E.

CS NewBiotics, Inc., San Diego, CA, 92121, USA

SO Biochemical Pharmacology (2003), 65(5), 823-831
 CODEN: BCPA6; ISSN: 0006-2952
 PB Elsevier Science Inc.
 DT Journal
 LA English
 AB NB1011 [E-5-(2-bromovinyl)-2'-deoxyuridine-5'-(l-methylalanyl)-phenylphosphoramidate], a phosphoramidate prodrug of E-5-(2-bromovinyl)-2'-deoxyuridine-5'-monophosphate (BVdUMP), is an investigational new anticancer drug. NB1011 targets thymidylate synthase (TS), which catalyzes the transformation of BVdUMP into cytotoxic reaction products. Due to the elevated levels of TS expression in tumor cells compared to normal cells, these cytotoxic products are preferentially generated inside tumor cells, and, as expected, NB1011 is more toxic to cells with higher levels of TS expression. Therefore, NB1011 therapy should kill tumor cells without severely damaging normal cells. Radiolabeled NB1011 was used to determine the intracellular fate of NB1011 reaction products and, possibly, the mechanism of action of this investigational new drug. We found significant incorporation of the radiolabel into cellular macromols. In contrast to our expectations that NB1011 product(s) would be incorporated into DNA, we discovered that cellular proteins were the labeled macromol. fraction. Herein, we report that the intracellular transformation of NB1011 involves formation of the corresponding monophosphate, TS-dependent transformation into highly reactive intermediates, and subsequent incorporation into cellular proteins. TS itself appears to escape irreversible inactivation. Our data suggest that protein modification not DNA incorporation accounts for the therapeutic effect of NB1011. The proposed mechanism is rather unexpected for a nucleotide analog and could lead to the discovery of new cellular protein targets for future drug design.
 IT 232925-18-7, NB1011
 RL: DMA (Drug mechanism of action); PKT (Pharmacokinetics); BIOL (Biological study)
 (cellular transformation of thymidylate synthase inhibitor anticancer drug NB1011, a phosphoramidate of 5-(2-bromovinyl)-2'-deoxyuridine, results in modification of cellular proteins not DNA)
 RN 232925-18-7 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
 RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 34 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2003:54370 CAPLUS
 DN 139:316719
 TI Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthiocinosine, selectively potentiate the antitumor activity of NB1011. [Erratum to document cited in CA138:248065]
 AU Boyer, Christopher R.; Karjian, Patricia L.; Wahl, Geoffrey M.; Pegram, Mark; Neuteboom, Saskia T. C.
 CS New Biotics, Inc., San Diego, CA, 92121, USA
 SO Anti-Cancer Drugs (2002), 13(10), 1077
 CODEN: ANTDEV; ISSN: 0959-4973
 PB Lippincott Williams & Wilkins

DT Journal
 LA English
 AB In the Results section, the second sentence should read: "The median-effect/combination index method by Chou and Talalay was used to calculate CI values.". The third sentence should read: "CI values < 1 indicate synergy, CI = 1 indicates additivity and CI > 1 indicates antagonism.".
 IT 232925-18-7, NB1011
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (dipyridamole and nitrobenzylthioinosine potentiate antitumor activity of NB1011 (Erratum))
 RN 232925-18-7 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridyllyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



L4 ANSWER 35 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2002:849374 CAPLUS
 DN 137:375228
 TI Viral enzyme activated prototoxophores and use of same to treat viral infections
 IN Cathers, Brian E.; Neuteboom, Saskia T. C.; Shepard, H. Michael
 PA Newbiotics, Inc., USA
 SO PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002087500	A2	20021107	WO 2002-US13223	20020426
	WO 2002087500	A9	20040408		
		W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW		
		RW:	GH, GM, KE, LS, MW, MZ, SD, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	AU 2002308479	A1	20021111	AU 2002-308479	20020426
	US 20030114385	A1	20030619	US 2002-133133	20020426
PRAI	US 2001-286893P	P	20010427		
	WO 2002-US13223	W	20020426		


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OS MARPAT 137:375228
 AB A synthetic prototoxophore, which is a relatively non-toxic compound that includes a toxin moiety and a substrate domain for a viral enzyme, is provided. Upon binding of a viral enzyme to the substrate domain, the catalytic activity of the viral enzyme converts the prototoxophore to a toxophore, which is toxic to a cell. Thus, a toxophore also is provided, as is a pharmaceutical composition containing a prototoxophore, and kits containing a

prototoxophore. Also provided are methods of using a prototoxophore to reduce or inhibit viral infectivity, and methods of using a prototoxophore to ameliorate the severity of a viral infection in an individual.

IT 474317-98-1
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (viral enzyme-activated prototoxophores to treat viral infections)
 RN 474317-98-1 CAPLUS
 CN Alanine, N-[5-(2-bromoethenyl)-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




L4 ANSWER 36 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2002:813406 CAPLUS
 DN 139:65584
 TI Electrospray ionization mass spectrometry of serine/alanine conjugated 5'-UMP and 3',5'-dithymidine phosphoramidates
 AU Qin, Zhi-Hui; Lin, Chang-Xue; Chen, Yi; Ju, Yong; Zhao, Yu-Fen
 CS Biooeg. Phosphorus Chem. Lab., Dep. of Chem., School of Life Sci. and Eng., Tsinghua Univ., Beijing, 100084, Peop. Rep. China
 SO Rapid Communications in Mass Spectrometry (2002), 16(20), 1997-2002
 CODEN: RCMSEF; ISSN: 0951-4198
 PB John Wiley & Sons Ltd.
 DT Journal
 LA English
 AB The structures of serine and alanine phosphoramidates of uridine and 3',5'-dithymidine were studied using pos. ion electrospray ionization mass spectrometry in conjunction with tandem mass spectrometry, and the proposed fragmentation pathways are reported. Besides the common elimination fragmentation pathway, ions originating from intramol. substitutions and rearrangements were observed for the serine phosphoramidate conjugates, reflecting the presence of the side-chain hydroxyl group. This behavior can be rationalized in terms of an attack of the hydroxyl group on the phosphorus atom with the aid of the sodium ion, to form a cyclic pentacoordinated phosphorane intermediate.
 IT 548775-54-8 548775-55-9
 RL: ANT (Analyte); ANST (Analytical study)
 (electrospray ionization mass spectrometry of serine/alanine conjugated 5'-UMP and 3',5'-dithymidine phosphoramidates)
 RN 548775-54-8 CAPLUS
 CN Thymidine, P-deoxy-P-[(1S)-2-methoxy-1-methyl-2-oxoethyl]amino]thymidylyl-(3'→5')-, 3'-acetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 548775-55-9 CAPLUS
 CN Thymidine, P-deoxy-P-[(1S)-1-(hydroxymethyl)-2-methoxy-2-oxoethyl]amino]thymidylyl-(3'→5')-, 3'-acetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 37 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2002:694508 CAPLUS
 DN 138:248065
 TI Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011
 AU Boyer, Christopher R.; Karjian, Patricia L.; Wahl, Geoffrey M.; Pegram, Mark; Neuteboom, Saskia T. C.
 CS NewBiotics, Inc, San Diego, CA, 92121, USA
 SO Anti-Cancer Drugs (2002), 13(1), 29-36
 CODEN: ANTDEV; ISSN: 0959-4973
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 AB NB1011, a novel anticancer agent, targets tumor cells expressing high levels of thymidylate synthase (TS). NB1011 is converted intracellularly to bromovinyldeoxyuridine monophosphate (BVdUMP) which competes with the natural substrate, deoxyuridine monophosphate, for binding to TS. Unlike inhibitors, NB1011 becomes a reversible substrate for TS catalysis. Thus, TS retains activity and converts BVdUMP into cytotoxic product(s). In vitro cytotoxicity studies demonstrate NB1011's preferential activity against tumor cells expressing elevated TS protein levels. Addnl., NB1011 has antitumor activity *in vivo*. To identify drugs which interact synergistically with NB1011, we screened 13 combinations of chemotherapeutic agents with NB1011 in human tumor and normal cells. Dipyridamole and p-nitrobenzylthioinosine (NBMPR), potent inhibitors of equilibrative nucleoside transport, synergized with NB1011 selectively against 5-fluorouracil (5-FU)-resistant H630R10 colon carcinoma cells [combination index (CI)=0.75 and 0.35] and Tomudex-resistant MCF7TDX breast carcinoma cells (CI=0.51 and 0.57), both TS overexpressing cell lines. These agents produced no synergy with NB1011 in Det551 and CCD18co normal cells (CI > 1.1) lacking TS overexpression. Dipyridamole potentiated NB1011's cytotoxicity in medium lacking nucleosides and bases, suggesting a non-salvage-dependent mechanism. We demonstrate that nucleoside transport inhibitors, dipyridamole and NBMPR, show promise for clin. efficacious combination with NB1011.
 IT 232925-18-7, NB1011
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (dipyridamole and nitrobenzylthioinosine potentiate antitumor activity of NB1011)
 RN 232925-18-7 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
 RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 38 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2002:688830 CAPLUS
 DN 137:295185
 TI An Improved Procedure for the Synthesis of Nucleoside Phosphoramidates
 AU Lehsten, Danielle M.; Baehr, David N.; Lobl, Thomas J.; Vaino, Andrew R.
 CS NewBiotics Inc., San Diego, CA, 92121, USA
 SO Organic Process Research & Development (2002), 6(6), 819-822
 CODEN: OPRDFK; ISSN: 1083-6160
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 137:295185
 GI



I

AB Nucleoside phosphoramidates, e.g. I, provide an elegant means to permit cellular absorption of masked phosphate esters, and, by doing so, remove any dependence of the biol. response on nucleoside kinase activity. The present report details a means to synthesize nucleoside phosphoramidates on a multi-pound scale with a high (>99%) degree of purity, suitable for use in human clin. trials.
 IT 232925-18-7P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (multi-pound scale synthesis of nucleoside phosphoramidates via condensation of alanine with Ph phosphorodichloridate)
 RN 232925-18-7 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 39 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2002:675850 CAPLUS
 DN 137:210903
 TI Use of 5-substituted nucleosides and/or prodrugs thereof in combination preparations for the resistance-free treatment of infectious diseases
 IN Fahrig, Rudolf Hinrich Hermann; Sonntag, Denise
 PA Resprotect G.m.b.H., Germany
 SO PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002067951	A2	20020906	WO 2002-EP1890	20020222
	WO 2002067951	A3	20030320		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 10108851	A1	20020912	DE 2001-10108851	20010223
	AU 2002234644	A1	20020912	AU 2002-234644	20020222
	EP 1368040	A2	20031210	EP 2002-701291	20020222
	EP 1368040	B1	20060705		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004526713	T	20040902	JP 2002-567317	20020222
	JP 4194366	B2	20081210		
	AT 332141	T	20060715	AT 2002-701291	20020222
	US 20040127454	A1	20040701	US 2004-468017	20040204
	US 7122528	B2	20061017		
PRAI	DE 2001-10108851	A	20010223		
	WO 2002-EP1890	W	20020222		
AB	The invention discloses the use of 5-substituted nucleosides and/or prodrugs thereof together with at least one active substance in order to produce a medicament or combination preparation used in the resistance-free treatment of infectious diseases caused by bacteria or protozoa.				
IT	232925-18-7 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nucleoside 5-substituted derivs. and/or prodrugs in combination preps. for resistance-free treatment of infectious disease)				
RN	232925-18-7 CAPLUS				
CN	L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)				

Absolute stereochemistry.
 Double bond geometry as shown.




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4	ANSWER 40 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
AN	2002:555307 CAPLUS
DN	137:103888
TI	Methods using pyrimidine derivatives and furanopyrimidone derivatives to treat autoimmune and inflammatory conditions
IN	Shepard, H. Michael
PA	Newbiotics, Inc., USA
SO	PCT Int. Appl., 65 pp. CODEN: PIXXD2
DT	Patent
LA	English
FAN.CNT 1	
	PATENT NO. KIND DATE APPLICATION NO. DATE
PI	WO 2002056832 A2 20020725 WO 2002-US1361 20020118
	WO 2002056832 A3 20030306
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
	CA 2441350 A1 20020725 CA 2002-2441350 20020118
	AU 2002241911 A1 20020730 AU 2002-241911 20020118
	AU 2002241911 B2 20061214
	AU 2002241911 B9 20070125
	US 20020151519 A1 20021017 US 2002-51320 20020118
	US 7138388 B2 20061121
	EP 1359921 A2 20031112 EP 2002-707508 20020118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
	US 20070213307 A1 20070913 US 2006-516457 20060905
PRAI	US 2001-262849P P 20010119
	US 2002-51320 A1 20020118
	WO 2002-US1361 W 20020118
	ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB	The invention provides methods for treating inflammatory or autoimmune diseases by contacting the affected cell or tissue with a therapeutic compound. Such pathologies include, but are not limited to, rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, reactive arthritis, Crohn's disease, ulcerative colitis, and scleroderma. Therapeutic compds. useful in the methods of this invention are selected from 1,5-substituted pyrimidine derivs. and analogs and substituted furanopyrimidone analogs. Compound preparation is included.
IT	322454-08-0 322454-10-4 322454-15-9 322454-32-0 322454-35-3 1101046-45-0 1101046-49-4 1101046-50-7 1101046-51-8 1101046-53-0
	RL: PRPH (Prophetic) (Methods using pyrimidine derivatives and furanopyrimidone derivatives to treat autoimmune and inflammatory conditions)
RN	322454-08-0 CAPLUS


CN L-Alanine, N-[2'-deoxy-P-phenyl-5-[(trimethylsilyl)ethynyl]-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322454-10-4 CAPLUS
CN L-Alanine, N-(2'-deoxy-5-ethynyl-P-phenyl-5'-uridylyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322454-15-9 CAPLUS
CN L-Alanine, N-[5-[(1E,3E)-4-bromo-1,3-butadienyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 322454-32-0 CAPLUS
CN L-Alanine, N-[5-(1-decynyl)-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 322454-35-3 CAPLUS
CN L-Alanine, N-(α, α, α -trifluoro-P-phenyl-5'-thymidyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 1101046-45-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry unknown.



RN 1101046-49-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
Double bond geometry as shown.



10/560, 887


RN 1101046-50-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry unknown.




RN 1101046-51-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry unknown.



RN 1101046-53-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
Double bond geometry unknown.



IT 322454-65-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyrimidine derivs. and furanopyrimidone derivs., for treatment of autoimmune and inflammatory conditions)

RN 322454-65-9 CAPLUS
CN L-Alanine, N-[5-(2-bromoethenyl)-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 41 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2002:391469 CAPLUS
 DN 136:386347
 TI Preparation of synergistic enzyme catalyzed therapeutic activation (ECTA) nucleosides as antitumor agents
 IN Shepard, H. Michael; Boyer, Christopher
 PA Newbiotics, Inc., USA
 SO PCT Int. Appl., 72 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002039952	A2	20020523	WO 2001-US43566	20011116	
	WO 2002039952	A3	20021010			
		W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
		RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
		AU	2002036455	A 20020527	AU 2002-36455	20011116
		US	20020147175	A1 20021010	US 2001-990799	20011116
PRAI	US 2000-249722P	P	20001116			
	WO 2001-US43566	W	20011116			


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB This invention provides compns. containing an effective amount of a novel substrate compound that selectively inhibit the proliferation of hyper-proliferative cells, for example, pathol. cells that endogenously over-express a target enzyme that confers resistance to biol. and chemo-therapeutic agents and an effective amount of a nucleoside transport antagonistic agents. Further provided by this invention is a method for treating a subject by delivering to the subject the composition as described herein. The compns. of this invention may be used alone or in combination with other chemo-therapeutics or alternative anti-cancer therapies such as radiation. Thus, (E)-5-(2-bromovinyl)-2'-deoxy-5'-uridyl Ph L-alaninylphosphoramidate (I) was prepared and tested in vitro human cells as synergistic antitumor agent. Vinblastine and doxorubicin showed potential synergy (CI < 1.1) with I in MCF7TDX and H630R10 cell. Irinotecan and taxol showed an additive or antagonistic interaction (CI = 1-1.4). The most antagonistic interaction was observed with 5-fluorouracil which gave CI = 3.19 in MCF7TDX cells. In light of these results, vinblastine and doxorubicin were chosen for further study.

IT 322454-65-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of synergistic enzyme catalyzed therapeutic activation nucleosides as antitumor agents)

RN 322454-65-9 CAPLUS
 CN L-Alanine, N-[5-(2-bromoethenyl)-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L4 ANSWER 42 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2002:328912 CAPLUS
 DN 137:272912
 TI Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, Bax, and GADD45 induction
 AU Neuteboom, Saskia T. C.; Karjian, Patricia L.; Boyer, Christopher R.; Beryt, Małgorzata; Pegram, Mark; Wahl, Geoffrey M.; Shepard, H. Michael
 CS NewBiotics, Inc., San Diego, CA, 92121, USA
 SO Molecular Cancer Therapeutics (2002), 1(6), 377-384
 CODEN: MCTOCF; ISSN: 1535-7163
 PB American Association for Cancer Research
 DT Journal
 LA English
 AB NB1011, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine, is a novel small mol. anticancer agent. NB1011 is selectively active against tumor cells expressing high levels of thymidylate synthase (TS), a critical enzyme in DNA biosynthesis. NB1011 is different from the current TS-targeted drugs, which require inhibition of TS to be effective, because NB1011 cytotoxicity depends upon activation by TS. Here we report a dose-dependent, antitumor activity of NB1011 against established Tomudex-resistant breast cancer (MCF7TDX) xenografts in athymic mice. Against 5-fluorouracil-resistant colon carcinoma (H630R10) xenografts, NB1011 was as efficacious as irinotecan, a drug recently approved for the treatment of 5-fluorouracil-resistant colon cancer. To gain insight into the mechanisms NB1011 uses to suppress cellular growth, we analyzed the downstream mol. events in the high TS-expressing MCF7TDX and RKOTDX cell lines upon NB1011 treatment. NB1011 treatment increased the mRNA levels of p21, Bax, and GADD45. Furthermore, NB1011 induced p53, p21, and Bax proteins specifically in high TS-expressing tumor cells, whereas no induction was observed in low TS-expressing tumor cells (MCF7) or normal cells (WI38). Cell cycle anal. demonstrated that NB1011 treatment of MCF7TDX and RKOTDX cells resulted in an accumulation of cells in the G2-M phase of the cell cycle. Altogether, our data indicate that the induction of the p53 target genes p21, bax, and GADD45, with a concomitant deregulation of the cell cycle, may represent one of the mechanisms by which NB1011 exerts its growth-suppressive effects.
 IT 232925-18-7, NB1011
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, Bax, and GADD45 induction)
 RN 232925-18-7 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
 RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 43 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2002:153907 CAPLUS
 DN 137:27792
 TI Synthesis and antiviral evaluation of phosphoramidate derivs. of (E)-5-(2-bromovinyl)-2'-deoxyuridine
 AU Harris, S. A.; McGuigan, C.; Andrei, G.; Snoeck, R.; De Clercq, E.; Balzarini, J.
 CS Welsh School of Pharmacy, Cardiff University, Cardiff, UK
 SO Antiviral Chemistry & Chemotherapy (2001), 12(5), 293-300
 CODEN: ACCHEH; ISSN: 0956-3202
 PB International Medical Press
 DT Journal
 LA English
 OS CASREACT 137:27792
 AB We report the design, synthesis and antiviral evaluation of a number of lipophilic, masked phosphoramidate derivs. of the antiherpetic agent (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), designed to act as membrane soluble prodrugs of the free nucleotide. The phosphoramidate derivs. of BVDU that contain L-alanine exhibited potent anti herpes simplex virus type 1 and varicella-zoster virus activity but lost marked activity against thymidine kinase-deficient virus strains. The phosphoramidate derivative bearing the amino acid α,α -dimethylglycine showed poor activity in all cell lines tested. It appears that successful kinase bypass by phosphoramidates is highly dependent on the nucleoside analog, amino acid and ester structure, as well as the cell line to which the drugs are exposed.
 IT 232925-18-7P 436097-54-0P 436097-55-1P
 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (synthesis and antiviral evaluation of phosphoramidate derivs. of (E)-5-(2-bromovinyl)-2'-deoxyuridine)
 RN 232925-18-7 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 436097-54-0 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 436097-55-1 CAPLUS
 CN Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



IT 436097-56-2P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis and antiviral evaluation of phosphoramidate derivs. of (E)-5-(2-bromovinyl)-2'-deoxyuridine)

RN 436097-56-2 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-P-(4-chlorophenyl)-2'-deoxy-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 44 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2001:167005 CAPLUS
DN 134:361084
TI A novel approach to thymidylate synthase as a target for cancer chemotherapy
AU Li, Qing; Boyer, Christopher; Lee, Jean Y.; Shepard, H. Michael
CS NewBiotics, Inc., San Diego, CA, USA
SO Molecular Pharmacology (2001), 59(3), 446-452
CODEN: MOPMA3; ISSN: 0026-895X
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
AB Tumor cell resistance to fluoropyrimidines and other inhibitors of thymidylate synthase (TS) is a serious problem often associated with increased intracellular TS. Clin., another problem that arises from the use of TS inhibitors is toxicity, which develops, in part, because normal cells may be adversely affected by doses of inhibitor that do not impact tumor cells. To circumvent this problem, we have devised a new strategy called enzyme-catalyzed therapeutic activation (ECTA), which takes advantage of overexpressed TS to enzymically generate cytotoxic moieties preferentially in tumor cells. We show herein that tumor cells expressing elevated levels of TS are preferentially sensitive to NB1011, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine. We find support for the proposed mechanism of NB1011 in the following results: (1) pos. relationship between TS protein level and sensitivity to NB1011 in engineered HT1080 tumor cells, designed to express defined levels of TS protein; (2) NB1011 activity is enhanced on tumor cells which express endogenous elevated TS; (3) cytotoxicity of NB1011 is blocked by raltitrexed (Tomudex); (4) NB1011 selection of TS-overexpressing MCF7TDX tumor cells results in recovery of cell populations and clones with diminished TS levels and restored sensitivity to raltitrexed. A preliminary comparison of TS mRNA levels in multiple normal tissues vs. colon tumor samples suggests that selective tumor cytotoxicity of NB1011 may be possible in the clin. setting. Because NB1011 cytotoxicity is dependent upon activation by TS, its proposed mechanism of action is distinct from current TS-targeted drugs, which require inhibition of TS to be effective.
IT 232925-18-7, NB1011
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(a novel approach to thymidylate synthase as a target for cancer chemotherapy)
RN 232925-18-7 CAPLUS
CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OSC.G 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 45 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2001:78399 CAPLUS
 DN 134:141727
 TI Enzyme-catalyzed therapeutic activation, tetrahydropyrimidine derivative prodrugs, and preparation and antitumor activity thereof
 IN Shepard, H. Michael; Chan, Ming Fai; Groziak, Michael P.
 PA Newbiotics, Inc., USA
 SO PCT Int. Appl., 106 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001007454	A1	20010201	WO 2000-US20008	20000721
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2379988	A1	20010201	CA 2000-2379988	20000721
	AU 2000062319	A	20010213	AU 2000-62319	20000721
	AU 775601	B2	20040805		
	EP 1200455	A1	20020502	EP 2000-948886	20000721
	EP 1200455	B1	20090422		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003505466	T	20030212	JP 2001-512538	20000721
	BR 2000012677	A	20030701	BR 2000-12677	20000721
	AT 429438	T	20090515	AT 2000-948886	20000721
	US 6683061	B1	20040127	US 2001-856127	20011010
	MX 2002000763	A	20020812	MX 2002-763	20020121
	US 20040077588	A1	20040422	US 2003-681418	20031007
	US 7605144	B2	20091020		
PRAI	US 1999-145356P	P	19990722		
	US 1999-145437P	P	19990723		
	US 2000-191315P	P	20000321		
	WO 2000-US20008	W	20000721		
	US 2001-856127	A1	20011010		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 134:141727

AB Substrate compds. are provided that selectively inhibit the proliferation of pathol. cells, e.g. pathol. cells that endogenously overexpress a target enzyme that confers resistance to biol. and chemotherapeutic agents. The enzyme acts on a substrate compound to (1) convert it to a cellular toxin and/or (2) release a toxic byproduct. In one embodiment, the activity of the target enzyme has been greatly enhanced in a target cell as a result of loss of tumor suppressor function and/or selection resulting from previous exposure to chemotherapy. In another embodiment, the pathol. cell contains a target enzyme that is an expression product of an infectious agent in the cell. Further provided is a method for treating a subject by delivering to the subject a prodrug as described herein. The prodrugs of the invention may be used alone or in combination with other therapeutics or alternative anti-cancer therapies such as radiation. Preparation of deoxyuridine derivs. is described.


IT 322454-65-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (enzyme-catalyzed therapeutic activation, tetrahydropyrimidine derivative prodrugs, and preparation and antitumor activity)

RN 322454-65-9 CAPLUS

CN L-Alanine, N-[5-(2-bromoethenyl)-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



IT 322453-87-2D, halo and cyano derivs. 322453-88-3
 322453-89-4 322453-90-7D, halo and cyano derivs.
 322453-91-8 322453-92-9 322453-93-0D, halo
 and cyano derivs. 322453-94-1 322453-96-3
 322453-98-5 322454-00-2 322454-02-4
 322454-02-4D, analogs 322454-04-6
 322454-04-6D, analogs 322454-08-0
 322454-10-4 322454-10-4D, analogs
 322454-15-9 322454-19-3 322454-21-7
 322454-23-9 322454-23-9D, analogs
 322454-26-2 322454-26-2D, analogs
 322454-29-5 322454-29-5D, analogs
 322454-32-0 322454-32-0D, analogs
 322454-35-3 322454-35-3D, analogs
 322454-69-3 322454-85-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(enzyme-catalyzed therapeutic activation, tetrahydropyrimidine derivative prodrugs, and preparation and antitumor activity)

RN 322453-87-2 CAPLUS

CN L-Alanine, N-[5-(1,3-butadienyl)-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 322453-88-3 CAPLUS

CN L-Alanine, N-[5-(4-chloro-1,3-butadienyl)-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 322453-89-4 CAPLUS

CN L-Alanine, N-[5-(4-bromo-1,3-butadienyl)-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 322453-90-7 CAPLUS

CN L-Alanine, N-[2'-deoxy-5-[(1E)-3-(diethylamino)-1-propenyl]-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 322453-91-8 CAPLUS

CN L-Alanine, N-[5-[(1E)-3-[bis(2-chloroethyl)amino]-1-propenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 322453-92-9 CAPLUS


CN L-Alanine, N-[5-[(1E)-3-[bis(2-bromoethyl)amino]-1-propenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 322453-93-0 CAPLUS
CN L-Alanine, N-[5-(1E)-1,3-butadienyl-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 322453-94-1 CAPLUS
CN L-Alanine, N-[2'-deoxy-5-[(1E)-4,4-dichloro-1,3-butadienyl]-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 322453-96-3 CAPLUS
CN L-Alanine, N-[5-[(1E,3E)-4-bromo-4-chloro-1,3-butadienyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 322453-98-5 CAPLUS
 CN L-Alanine, N-[5-[(1E,3Z)-4-bromo-4-chloro-1,3-butadienyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 322454-00-2 CAPLUS
 CN L-Alanine, N-[2'-deoxy-5-[(1E)-4,4-dibromo-1,3-butadienyl]-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 322454-02-4 CAPLUS
 CN L-Alanine, N-[2'-deoxy-5-[(1E)-3-[(4-oxo-4H-1,3-dioxin-6-yl)oxy]-1-propenyl]-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 322454-02-4 CAPLUS

CN L-Alanine, N-[2'-deoxy-5-[(1E)-3-[(4-oxo-4H-1,3-dioxin-6-yl)oxy]-1-propenyl]-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 322454-04-6 CAPLUS

CN L-Alanine, N-[2'-deoxy-5-[(1E)-3-[(5-methyl-4-oxo-4H-1,3-dioxin-6-yl)oxy]-1-propenyl]-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 322454-04-6 CAPLUS

CN L-Alanine, N-[2'-deoxy-5-[(1E)-3-[(5-methyl-4-oxo-4H-1,3-dioxin-6-yl)oxy]-1-propenyl]-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 322454-08-0 CAPLUS


CN L-Alanine, N-[2'-deoxy-P-phenyl-5-[(trimethylsilyl)ethynyl]-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 322454-10-4 CAPLUS
CN L-Alanine, N-(2'-deoxy-5'-ethynyl-P-phenyl-5'-uridylyl)-, methyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322454-10-4 CAPLUS
CN L-Alanine, N-(2'-deoxy-5'-ethynyl-P-phenyl-5'-uridylyl)-, methyl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322454-15-9 CAPLUS
CN L-Alanine, N-[5-[(1E,3E)-4-bromo-1,3-butadienyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 322454-19-3 CAPLUS
 CN L-Alanine, N-[5-[(1E,3Z)-4-bromo-1,3-butadienyl]-2'-deoxy-P-phenyl-5'-uridyllyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 322454-21-7 CAPLUS
 CN 2,4-Pentadienoic acid, 5-[1-[2-deoxy-5-O-[[[(1S)-2-methoxy-1-methyl-2-oxoethyl]amino]phenoxyphosphinyl]-β-D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-, ethyl ester, (2E,4E)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 322454-23-9 CAPLUS
 CN 2,4-Pentadienoic acid, 5-[1-[2-deoxy-5-O-[[[(1S)-2-methoxy-1-methyl-2-oxoethyl]amino]phenoxyphosphinyl]-β-D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.




RN 322454-23-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-[1-[2-deoxy-5-O-[(1S)-2-methoxy-1-methyl-2-oxoethyl]amino]phenoxyphosphinyl]-beta-D-erythro-pentofuranosyl-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.




RN 322454-26-2 CAPLUS

CN L-Alanine, N-[5-[(1E)-4-chloro-1,3-butadienyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.




RN 322454-26-2 CAPLUS

CN L-Alanine, N-[5-[(1E)-4-chloro-1,3-butadienyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as described by E or Z.




RN 322454-29-5 CAPLUS
 CN L-Alanine, N-[5-[(1E)-4-bromo-1,3-butadienyl]-2'-deoxy-P-phenyl-5'-uridyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.




RN 322454-29-5 CAPLUS
 CN L-Alanine, N-[5-[(1E)-4-bromo-1,3-butadienyl]-2'-deoxy-P-phenyl-5'-uridyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.



RN 322454-32-0 CAPLUS
 CN L-Alanine, N-[5-(1-decynyl)-2'-deoxy-P-phenyl-5'-uridyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322454-32-0 CAPLUS

CN L-Alanine, N-[5-(1-decynyl)-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322454-35-3 CAPLUS

CN L-Alanine, N-(alpha,alpha,alpha-trifluoro-P-phenyl-5'-thymidylyl)-,
methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322454-35-3 CAPLUS

CN L-Alanine, N-(alpha,alpha,alpha-trifluoro-P-phenyl-5'-thymidylyl)-,
methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322454-69-3 CAPLUS


CN L-Alanine, N-[5-[(1E)-2-chloroethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-,
methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 322454-85-3 CAPLUS
 CN L-Alanine, N-(2'-deoxy-P-phenyl-5'-uridylyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
 RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 46 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2001:24117 CAPLUS
 DN 134:290064
 TI Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase
 AU Lackey, D. B.; Groziak, M. P.; Sergeeva, M.; Beryt, M.; Boyer, C.; Stroud, R. M.; Sayre, P.; Park, J. W.; Johnston, P.; Slamon, D.; Shepard, H. M.; Pegram, M.
 CS NewBiotics, Inc., San Diego, CA, 92121, USA
 SO Biochemical Pharmacology (2001), 61(2), 179-189
 CODEN: BCPKA6; ISSN: 0006-2952
 PB Elsevier Science Inc.
 DT Journal
 LA English
 AB The in vivo administration of enzyme-inhibiting drugs for cancer and infectious disease often results in overexpression of the targeted enzyme. We have developed an enzyme-catalyzed therapeutic agent (ECTA) approach in which an enzyme overexpressed within the resistant cells is recruited as an intracellular catalyst for converting a relatively non-toxic substrate to a toxic product. We have investigated the potential of the ECTA approach to circumvent the thymidylate synthase (TS) overexpression-based resistance of tumor cells to conventional fluoropyrimidine [i.e. 5-fluorouracil (5-FU)] cancer chemotherapy.
 (E)-5-(2-Bromovinyl)-2'-deoxy-5'-uridyl Ph
 1-methoxyalaninylphosphoramidate (NB1011) is a pronucleotide analog of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdU), an antiviral agent known to be a substrate for TS when in the 5'-monophosphorylated form. NB1011 was synthesized and found to be at least 10-fold more cytotoxic to 5-FU-resistant, TS-overexpressing colorectal tumor cells than to normal cells. This finding demonstrates that the ECTA approach to the design of novel therapeutics results in compds. that are selectively cytotoxic to tumor cell lines that overexpress the target enzyme, TS, and therefore may be useful in the treatment of fluoropyrimidine-resistant cancer.
 IT 232925-18-7, NB 1011

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (enzyme-catalyzed therapeutic agent design: activation of antitumor
 NB1011 by thymidylate synthase)

RN 232925-18-7 CAPLUS
 CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




OSC.G 20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (21 CITINGS)
 RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 47 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1999:757496 CAPLUS
 DN 132:137652
 TI Potential Multifunctional Inhibitors of HIV-1 Reverse Transcriptase. Novel [AZT]-[TSAO-T] and [d4T]-[TSAO-T] Heterodimers Modified in the Linker and in the Dideoxynucleoside Region
 AU Velazquez, Sonsoles; Tunon, Victoria; Jimeno, Maria Luisa; Chamorro, Cristina; De Clercq, Erik; Balzarini, Jan; Camarasa, Maria Jose
 CS Instituto de Quimica Medica (C.S.I.C.), Madrid, 28006, Spain
 SO Journal of Medicinal Chemistry (1999), 42(25), 5188-5196
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 AB In an attempt to combine the anti-HIV-inhibitory capacity of nucleoside reverse transcriptase (RT) inhibitors (NRTI) and non-nucleoside RT inhibitors (NNRTI), several heterodimer analogs of the previously reported [AZT]-[CH₂]₃-[TSAO-T] prototype have been prepared. In these novel series, other NRTIs, an expanded range of linkers with different conformational freedom and other attachment sites for these linkers on the base part of the NRTI analog have been explored. Moreover, in order to circumvent the dependence of the NRTI moiety of the heterodimer on activation by cellular nucleoside kinases, novel heterodimers in which the NRTI is bearing a masked monophosphate group at the 5'-position are described. Among the novel heterodimers, several derivs. show a potent anti-HIV-1 activity, which proved comparable, or even superior, to that of the AZT heterodimer prototype. The nature of the NRTI was important for the eventual anti-HIV-1 activity. In particular, the d4T heterodimer derivative containing a Pr linker between the N-3 positions of the base of TSAO-T and d4T was apprx. 5- to 10-fold more inhibitory to HIV-1 than the corresponding AZT heterodimer prototype.
 IT 256520-37-3P 256520-41-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 ([AZT]-[TSAO-T] and [d4T]-[TSAO-T] heterodimers modified in the linker and in the dideoxynucleoside region as potential multifunctional inhibitors of HIV reverse transcriptase)
 RN 256520-37-3 CAPLUS
 CN L-Alanine, N-[3-[3-[3-[(5R,6R,8R,9R)-4-amino-9-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2,2-dioxido-1,7-dioxa-2-


thiaspiro[4.4]non-3-en-8-yl]-3,6-dihydro-5-methyl-2,6-dioxo-1(2H)-pyrimidinylpropyl]-P-phenyl-5'-thymidylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 256520-41-9 CAPLUS
 CN L-Alanine, N-[3-[6-[3-[(5R,6R,8R,9R)-4-amino-9-[(1,1-dimethylethyl)dimethylsilyl]oxy]-6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2,2-dioxido-1,7-dioxa-2-thiaspiro[4.4]non-3-en-8-yl]-3,6-dihydro-5-methyl-2,6-dioxo-1(2H)-pyrimidinylhexyl]-P-phenyl-5'-thymidylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






IT 256520-25-9P 256520-29-3P 256520-33-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 ([AZT]-[TSAO-T] and [d4T]-[TSAO-T] heterodimers modified in the linker
 and in the dideoxynucleoside region as potential multifunctional
 inhibitors of HIV reverse transcriptase)

RN 256520-25-9 CAPLUS

CN L-Alanine, N-(P-phenyl-5'-thymidylyl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 256520-29-3 CAPLUS

CN L-Alanine, N-[3-(3-bromopropyl)-P-phenyl-5'-thymidylyl]-, methyl ester
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 256520-33-9 CAPLUS

CN L-Alanine, N-[3-(6-bromohexyl)-P-phenyl-5'-thymidylyl]-, methyl ester
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



OSC.G 21 THERE ARE 21 CAPLUS RECORDS THAT CITE THIS RECORD (21 CITINGS)
 RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 48 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1999:499942 CAPLUS
 DN 131:257780
 TI 5'-Phosphoramides and 5'-Diphosphates of
 2'-O-Allyl- β -D-arabinofuranosyl-uracil, -cytosine, and -adenine:
 Inhibition of Ribonucleotide Reductase
 AU Manfredini, Stefano; Baraldi, Pier Giovanni; Durini, Elisa; Vertuani,
 Silvia; Balzarini, Jan; De Clercq, Erik; Karlsson, Anna; Buzzoni,
 Valentina; Thelander, Lars
 CS Department of Pharmaceutical Sciences, Ferrara University, Italy
 SO Journal of Medicinal Chemistry (1999), 42(17), 3243-3250
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 AB Continuing our studies on ribonucleotide reductase (RNR) mechanism-based
 inhibitors, we have now prepared the diphosphates (DP) of
 2'-O-allyl-1- β -D-arabinofuranosyl-uracil and -cytosine and
 2'-O-allyl-9- β -D-arabinofuranosyl-adenine and evaluated their
 inhibitory activity against recombinant murine RNR. 2'-O-Allyl-araUDP
 proved to be inhibitory to RNR at an IC₅₀ of 100 μ M, whereas
 2'-O-allyl-araCDP was only marginally active (IC₅₀ 1 mM) and
 2'-O-allyl-araADP was completely inactive. The susceptibility of the
 parent nucleosides to phosphorylation by thymidine kinase and
 2'-deoxycytidine kinase was also investigated, and all nucleosides proved
 to be poor substrates for the above-cited kinases. Moreover, prodrugs of
 2'-O-allyl-araU and -araC monophosphates, namely
 2'-O-allyl-5'-(phenylethoxy-L-alanyl phosphate)-araU and -araC, were
 prepared and tested against tumor cell proliferation but proved to be
 inactive. A mol. modeling study has been conducted in order to explain
 our results. The data confirm that for both the natural and analog
 nucleoside diphosphates, the principal determinant interaction with the
 active site of RNR is with the diphosphate group, which forms strong
 hydrogen bonds with Glu623, Thr624, Ser625, and Thr209. Our findings
 indicate that the poor phosphorylation may represent an explanation for
 the lack of marked in vitro cytostatic activity of the test compds.
 IT 239117-80-7P 245078-09-5P
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological
 process); BSU (Biological study, unclassified); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
 (preparation and ribonucleotide reductase inhibition of phosphoramides and
 diphosphates of allyl-D-arabinofuranosyl-uracil, -cytosine and
 -adenine)
 RN 239117-80-7 CAPLUS
 CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[[[(1S)-2-ethoxy-1-methyl-2-
 oxoethyl]amino]phenoxyphosphinyl]-2-O-2-propen-1-yl- β -D-
 arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 245078-09-5 CAPLUS
 CN L-Alanine, N-[[1-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-deoxy-2-O-2-propenyl-
 β -D-arabinofuranos-5-O-yl]phenoxyphosphinyl]-, ethyl ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



OSC.G 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)
 RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4	ANSWER 49 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN				
AN	1999:487370 CAPLUS				
DN	131:111426				
TI	Method for drug screening and enzyme-activated phosphoryl or phosphoramidate prodrugs and their synthesis and use in inhibition of cell proliferation				
IN	Shepard, H. Michael; Groziak, Michael P.				
PA	Newbiotics, Inc., USA				
SO	PCT Int. Appl., 113 pp. CODEN: PIXXD2				
DT	Patent				
LA	English				
FAN.CNT	2				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9937753	A1	19990729	WO 1999-US1332	19990122
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA	2317505	A1	19990729	CA 1999-2317505	19990122
AU	9924646	A	19990809	AU 1999-24646	19990122
AU	753155	B2	20021010		
BR	9907736	A	20001017	BR 1999-7736	19990122
EP	1045897	A1	20001025	EP 1999-904195	19990122
EP	1045897	B1	20020130		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US	6245750	B1	20010612	US 1999-235809	19990122
EP	1167972	A2	20020102	EP 2001-120242	19990122
EP	1167972	A3	20060524		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP	2002500880	T	20020115	JP 2000-528661	19990122
AT	212661	T	20020215	AT 1999-904195	19990122
PT	1045897	E	20020731	PT 1999-904195	19990122
ES	2172303	T3	20020916	ES 1999-904195	19990122
CN	1192102	C	20050309	CN 1999-803221	19990122
TW	244924	B	20051211	TW 1999-88101009	19990122
MX	2000006993	A	20010507	MX 2000-6993	20000717
JP	2001220397	A	20010814	JP 2000-339831	20001108
JP	3265304	B2	20020311		
HK	1030624	A1	20020614	HK 2001-100891	20010208
PRAI	US 1998-72264P	P	19980123		
	US 1998-76950P	P	19980305		
	US 1998-108634P	P	19981116		
	EP 1999-904195	A3	19990122		
	JP 2000-528661	A3	19990122		
	WO 1999-US1332	W	19990122		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OS CASREACT 131:111426; MARPAT 131:111426

AB This invention provides a method for identifying potential therapeutic agents by contacting a target cell with a candidate therapeutic agent which is a selective substrate for an endogenous, intracellular enzyme in the cell which is enhanced in its expression as a result of selection by biol. or chemotherapy. This invention also provides methods and examples of mols. for selectively killing a pathol. cell by contacting the cell with a prodrug that is a selective substrate for an endogenous, intracellular enzyme. The prodrug is subsequently converted to a cellular toxin. Further provided by this invention is a method for treating a pathol. characterized by pathol., hyperproliferative cells in a subject by administering to the subject a prodrug that is a selective substrate for an endogenous, overexpressed, intracellular enzyme, and converted by the enzyme to a cellular toxin in the hyperproliferative cell. Thus, E-5-(2-bromovinyl)-2'-deoxy-5'-uridyl Ph L-alaninylphosphoramidate (BVDU-PA) was prepared by reacting E-5-(2-bromovinyl)-2'-deoxyuridine with Ph L-methoxyalaninyl phosphorochloridate in anhydrous DMF in the presence of imidazole (HCl scavenger). BVDU-PA was added to H630R10 cells and to CCD18co control cells. H630R10 cells expressed 10-fold more thymidylate synthase enzyme than CCD18co cells. BVDU-PA displayed IC50's of 217 and 2810 μ M on the H630R10 cells and CCD18co cells, resp.

IT 232925-18-7P 232925-20-1P

RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)


(method for drug screening and enzyme-activated phosphoryl or phosphoramidate prodrugs and their synthesis and use in inhibition of cell proliferation)

RN 232925-18-7 CAPLUS

CN L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 232925-20-1 CAPLUS

CN L-Alanine, N-(2'-deoxy-5-fluoro-P-phenyl-5'-uridylyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 232925-21-2 232925-22-3 232925-23-4

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(method for drug screening and enzyme-activated phosphoryl or phosphoramidate prodrugs and their synthesis and use in inhibition of cell proliferation)


RN 232925-21-2 CAPLUS
 CN L-Alanine, N-[2'-deoxy-5-[(1E)-3-[[bis(1-aziridinyl)phosphinyl]oxy]-1-propenyl]-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 232925-22-3 CAPLUS
 CN L-Alanine, N-[2'-deoxy-5-[(1Z)-3-[[bis(1-aziridinyl)phosphinyl]oxy]-1-propenyl]-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 232925-23-4 CAPLUS
 CN L-Alanine, N-[2'-deoxy-5-[3-[[bis(1-aziridinyl)phosphinyl]oxy]-1-propynyl]-P-phenyl-5'-uridylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




OSC.G 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
 RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 50 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1999:448710 CAPLUS
 DN 131:170568
 TI Synthesis, cytostatic activity and inhibition of ribonucleotide reductase by 5'-phosphoramides and 5'-diphosphates, of 2'-O-allyl-arabinofuranosyl nucleosides
 AU Manfredini, S.; Baraldi, P. G.; Durini, E.; Balzarini, J.; De Clercq, E.; Karlsson, A.; Buzzoni, V.; Thelander, L.
 CS Department of Pharmaceutical Sciences, Ferrara University, Italy
 SO Nucleosides & Nucleotides (1999), 18(4 & 5), 1007-1008
 CODEN: NUNUD5; ISSN: 0732-8311
 PB Marcel Dekker, Inc.
 DT Journal
 LA English
 AB A symposium reporting that the diphosphates of a series of 2'-O-allyl-1-β-D-arabinofuranosyl derivs., previously obtained by the

authors, have been prepared and tested for their inhibitory activity in an *in vitro* assay using R1 and R2 subunits of the purified recombinant mouse ribonucleotide reductase (RNR). 2'-O-Allyl-araU diphosphate proved to be inhibitory, with an IC₅₀ of 100 μM. The 5'-phosphoramidate pronucleotide of 2'-O-allyl-araU was also prepared and tested for inhibition of tumor cell proliferation.

- IT 239117-80-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, cytostatic activity and inhibition of ribonucleotide reductase by phosphoramidates and diphosphates of allylarabinofuranosyl nucleosides)
- RN 239117-80-7 CAPLUS
- CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[[[(1S)-2-ethoxy-1-methyl-2-oxoethyl]amino]phenoxyphosphinyl]-2-O-2-propen-1-yl-β-D-arabinofuranosyl] - (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L4 ANSWER 51 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1998:382225 CAPLUS
 DN 129:49222
 OREF 129:10111a,10114a
 TI Synthesis and evaluation of some masked phosphate esters of the anti-herpesvirus drug 882C (netivudine) as potential antiviral agents
 AU McGuigan, C.; Perry, A.; Yarnold, C. J.; Sutton, P. W.; Lowe, D.; Miller, W.; Rahim, S. G.; Slater, M. J.
 CS Welsh School of Pharmacy, University of Wales Cardiff, Cardiff, CF1 3XF, UK
 SO Antiviral Chemistry & Chemotherapy (1998), 9(3), 233-243
 CODEN: ACCHEH; ISSN: 0956-3202
 PB International Medical Press
 DT Journal
 LA English
 AB A number of sym. and asym. 5'-phosphate esters of the potent anti-varicella-zoster virus (VZV) agent 1-β-D-arabinofuranosyl-5-(1-propynyl)uracil (netivudine) were prepared as potential lipophilic, membrane-soluble prodrugs of the bioactive phosphate forms. The compds. were prepared by the base-catalyzed coupling of various phosphorochloridates with the free nucleoside analog. The compds. were fully characterized by a range of spectroscopic and anal. methods and were studied for their inhibition of several viruses in tissue culture. All of the phosphate esters were inactive against human cytomegalovirus, herpes simplex virus type 2, VZV, human immunodeficiency virus type 1 and influenza A virus (EC₅₀ >100 μM) except the 5'-(4-nitrophenyl Ph phosphate), which inhibited influenza A virus. The relative rate of esterase-mediated hydrolysis of netivudine 5'-(L-methoxyalaninyl Ph phosphate) was measured in order to rationalize the poor antiviral action, and data were collected on possible metabolites in support of this anal. Cell-specific esterases are implicated as key determinants of the antiviral potency of prodrugs of this type.
 IT 208777-84-8P, Netivudine 5'-(L-methoxyalaninyl phenyl phosphate)
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
 (preparation and evaluation of some masked phosphate esters of 882C


(netivudine) as antiviral agents)
 RN 208777-84-8 CAPLUS
 CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[[[(1S)-2-methoxy-1-methyl-2-oxoethyl]amino]phenoxyphosphinyl]- β -D-arabinofuranosyl]-5-(1-propyn-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




IT 208777-85-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and evaluation of some masked phosphate esters of 882C (netivudine) as antiviral agents)
 RN 208777-85-9 CAPLUS
 CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[[[(1S)-1-(methoxycarbonyl)-2-methylpropyl]amino]phenoxyphosphinyl]- β -D-arabinofuranosyl]-5-(1-propyn-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
 RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 52 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1997:334014 CAPLUS
 DN 127:50955
 OREF 127:9729a,9732a
 TI Phosphorus-based combinatorial libraries: use of amino acid derivatives as synthons
 AU Fathi, Reza; Patel, Rina; Cook, Alan F.
 CS PharmaGenics Inc., Allendale, NJ, 07401, USA
 SO Molecular Diversity (1997), 2(3), 125-134
 CODEN: MODIF4; ISSN: 1381-1991
 PB ESCOM
 DT Journal
 LA English
 GI



AB Phosphorus has been used as a scaffold to prepare phosphoramidate

combinatorial libraries I [HO-R1-OH, HO-R2-OH = variable bifunctional group containing two hydroxy functions; R3 = Met-OEt, Ala-OMe, Val-OEt, Glu(OEt)-OEt, Phe-OMe, Tyr-OEt, Leu-OCMe₃, Ile-OCMe₃, Trp-OMe, Pro-OMe, Asp(OCMe₃)-OCMe₃] which one of the diversity elements resulted from amino acid derivs. A small library was prepared for anal. and characterization purposes, followed by a larger library of approx. 8800 compds. Libraries were assembled on solid supports using the conventional pool-and-divide method, followed by cleavage from the supports at the end of the synthesis. Mass spectrometry was used to confirm that library synthesis had been successful. Individual compds. were also prepared to study the stability of compds. of this type.

IT 191017-38-6P 191017-39-7P 191017-40-0P


191017-42-2P 191017-43-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(amino acid derivs. as synthons in preparation of phosphorus-based combinatorial libraries)

RN 191017-38-6 CAPLUS

CN L-Methionine, N-[P-(5'-deoxythymidin-5'-yl)-3'-thymidylyl]-, ethyl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191017-39-7 CAPLUS

CN L-Tyrosine, N-[P-(5'-deoxythymidin-5'-yl)-3'-thymidylyl]-, ethyl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191017-40-0 CAPLUS


CN L-Valine, N-[P-(5'-deoxythymidin-5'-yl)-3'-thymidylyl]-, ethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 191017-42-2 CAPLUS
 CN L-Isoleucine, N-[P-(5'-deoxythymidin-5'-yl)-3'-thymidyllyl]-, 1,1-dimethyl ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191017-43-3 CAPLUS
 CN L-Glutamic acid, N-[P-(5'-deoxythymidin-5'-yl)-3'-thymidyllyl]-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 53 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1990:552990 CAPLUS
 DN 113:152990
 OREF 113:26023a,26026a
 TI Oligonucleotides and nucleotide peptides. LIII. Synthesis and properties of thymidyllyl-(5'→3')-thymidine-(PM→N)-serine ethyl ester
 AU Juodka, B.; Bagdoniene, L.
 CS Vil'nyus. Gos. Univ., Vilnius, USSR
 SO Khimiya Prirodnikh Soedinenii (1990), (1), 88-93
 CODEN: KPSUAR; ISSN: 0023-1150

DT Journal
 LA Russian
 OS CASREACT 113:152990
 GI




AB Treating TpT as its tri-n-octylammonium salt with H-Ser-OEt (1:3) in pyridine containing triisopropylbenzenesulfonyl chloride, N-methylimidazole, and Et3N gave 38% yield of a mixture containing diastereomeric oligonucleotide amino acids I and II. On treatment of I and II with 1N HCl, the phosphoamide undergoes 20% N → O migration. In basic media, compared to other nucleotide peptides, decomposition of phosphoamide bonds in I and II occurs.


IT 129704-55-8P 129704-56-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and acid-base treatment of)

RN 129704-55-8 CAPLUS

CN L-Serine, N-3'-thymidylyl-, 1-ethyl ester, P \rightarrow 5'-ester with thymidine, (R)- (9CI) (CA INDEX NAME)



RN 129704-56-9 CAPLUS
 CN L-Serine, N-3'-thymidylyl-, 1-ethyl ester, P \rightarrow 5'-ester with thymidine, (S)- (9CI) (CA INDEX NAME)



L4 ANSWER 54 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1986:225188 CAPLUS
 DN 104:225188
 QREF 104:35735a,35738a
 TI Thymidine nucleosides
 IN Letsinger, Robert L.; Schott, Margaret E.
 PA United States Dept. of Health and Human Services, USA

SO U.S., 9 pp. Cont. of U.S. Ser. No. 444,438, abandoned.
CODEN: USXXAM

DT Patent
LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4547569	A	19851015	US 1984-620801	19840614
	US 444438	A0	19840817	US 1982-444438	19821124
PRAI	US 1982-444438	A2	19821124		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OS CASREACT 104:225188
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Th = 1-thyminyl throughout this abstract Nucleotides I (R = R1 are MeNH, EtNH, NH₂, H; Z1 = alkylene; n is an integer of 0-19) were prepared, and they showed their usefulness as fluorescent probes. Two different thymidine derivs. were treated with 2-ClC₆H₄OPCl₂, and the phosphite triester obtained was converted, in a series of reactions, to nucleotide derivative II.

IT 93084-42-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and amidation of, by butanediamine, selective deprotection in)
RN 93084-42-5 CAPLUS
CN Thymidine, P-deoxy-P-[(2-ethoxy-2-oxoethyl)amino]-5'-O-
(phenoxyacetyl)thymidylyl-(3'→5')-3'-O-[(4-
methoxyphenyl)diphenylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




OSC.G 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 55 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
AN 1984:611660 CAPLUS
DN 101:211660
OREF 101:32091a,32094a
TI Intercalating agents specifying nucleotides
IN Letsinger, Robert L.; Schott, Margaret E.
PA United States Dept. of Health and Human Services, USA
SO U. S. Pat. Appl., 16 pp. Avail. NTIS Order No. PAT-APPL-6-444 438.
CODEN: XAXXAV
DT Patent

LA English


FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 444438	A0	19840817	US 1982-444438	19821124
US 4547569	A	19851015	US 1984-620801	19840614
PRAI US 1982-444438	A2	19821124		


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
GI

- AB Phenanthridinium compds. I (Th = thymin-1-yl; R, R1 = H, NH₂, MeNH, EtNH,) were prepared I can serve as site specific inhibitors for enzymic processes involving polynucleotides, as reagents for selective cleavage or modification of polynucleotide chains, and as agents for introducing markers, e.g., fluorescent probes, at specified regions in polynucleotides. Thus, I (R = R1 = NH₂) (II) was prepared by constructing the nucleotide portion containing the NHCH₂CONH(CH₂)₄NH₂ group, and the p-nitrophenyl ester of the phenanthridinium unit and linking the 2 fragments via an amide bond. II binds strongly to poly(A) at 0° and weakly or not at all to poly(G), poly(C), poly(U), and poly(I).
- IT 93084-42-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and amidation, with diaminobutane)
- RN 93084-42-5 CAPLUS
- CN Thymidine, P-deoxy-P-[(2-ethoxy-2-oxoethyl)amino]-5'-O-(phenoxyacetyl)thymidylyl-(3'→5')-3'-O-[(4-methoxyphenyl)diphenylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 56 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1983:198675 CAPLUS
 DN 98:198675
 OREF 98:30231a,30234a
 TI Oligonucleotides and nucleotide peptides. XLIII. Efficiency of the intramolecular effect of the carboxyl group of amino acids in nucleotidyl-(P → N)-amino acids (peptides) in relation to its position
 AU Juodka, B.; Liorancaite, L.; Baltenas, V.
 CS Vil'nyuss. Gos. Univ., Vilnius, USSR
 SO Khimiya Prirodnnykh Soedinenii (1982), (6), 740-6
 CODEN: KPSUAR; ISSN: 0023-1150
 DT Journal
 LA Russian
 AB Title compds., e.g., deoxythymidylyl(5'→N)phenylalanine (I), were prepared and their hydrolytic stabilities were examined. The phenylalanine carboxyl group in I is much more effective than that in the (3'→N)-analog of I in promoting intramol. catalysis of hydrolysis. The carboxyl group in oligonucleotidyl(P'm → N) amino acids is responsible for cleavage of the phospho ester bond in acidic medium.
 IT 81202-42-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 81202-42-8 CAPLUS
 CN Thymidine, P-deoxy-P-[[2-ethoxy-2-oxo-1-(phenylmethyl)ethyl]amino]thymidylyl-(3'→5')-, (S)- (9CI) (CA INDEX NAME)



L4 ANSWER 57 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1982:143270 CAPLUS
 DN 96:143270
 OREF 96:23585a,23588a
 TI Synthesis and some properties of oligonucleotidyl-(Pm → N)-serines
 AU Liorancaite, L.; Juodka, B.
 CS Vilnius State Univ., Vilnius, USSR

SO Nucleic Acids Symposium Series (1981), 9, 215-18
 CODEN: NACSD8; ISSN: 0261-3166

DT Journal

LA English

GI For diagram(s), see printed CA Issue.


AB Nucleotidyl amino acids I-VI were prepared by condensing TpT or TpdC with the amino acid derivative by (PhO)₂P(O)Cl, TPS, or carbonyldiimidazole (CDI). The CDI method gave the best results. III underwent an N \rightarrow O migration in acid, whereas the phosphoamide bond was cleaved in alkaline medium.

IT 78396-63-1P 81136-03-0P 81202-42-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 78396-63-1 CAPLUS

CN L-Serine, N-3'-thymidylyl-, 1-ethyl ester, P \rightarrow 5'-ester with thymidine (9CI) (CA INDEX NAME)




RN 81136-03-0 CAPLUS

CN Thymidine, P,2'-dideoxy-P-[2-ethoxy-1-(hydroxymethyl)-2-oxoethyl]amino]cytidylyl-(5' \rightarrow 3')-, (S)- (9CI) (CA INDEX NAME)



RN 81202-42-8 CAPLUS

CN Thymidine, P-deoxy-P-[2-ethoxy-2-oxo-1-(phenylmethyl)ethyl]amino]thymidylyl-(3' \rightarrow 5')-, (S)- (9CI) (CA INDEX NAME)



L4 ANSWER 58 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN

AN 1982:7023 CAPLUS

DN 96:7023

OREF 96:1287a,1290a

TI Selectivity in binding a phenanthridinium-dinucleotide derivative to homopolynucleotides

AU Letsinger, Robert L.; Schott, Margaret E.

CS Dep. Chem., Northwestern Univ., Evanston, IL, 60201, USA
 SO Journal of the American Chemical Society (1981), 103(24), 7394-6
 CODEN: JACSAT; ISSN: 0002-7863

DT Journal

LA English

GI For diagram(s), see printed CA Issue.

AB Dinucleotide I was synthesized as a prototype of a mol. bearing a biol. active group (diaminomethylphenylphenanthridinium) joined covalently to an oligonucleotide recognition system (thymidylylthymidine) by a linker that permits intercalation of the active group in the pocket formed by the nucleotide and complementary bases in another polynucleotide strand. Spectrophotometric data show that I binds strongly to poly(A) at 0° and weakly or not at all with poly(G), poly(C), poly(U) and poly(I). On warming, the complex with poly(A) dissociates. (T_m apprx. 47° in absence of salt, apprx. 25° in 0.1M NaCl; T_m = melting temperature). The strong interaction of I with poly(A) is attributed to the presence of 2 types of binding sites in I which can act cooperatively, the phenanthridinium ring and the pyrimidine bases (which show Watson-Crick type selectivity).

IT 79999-73-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, with diaminobutane)

RN 79999-73-8 CAPLUS


CN Thymidine, P-deoxy-P-[(2-ethoxy-2-oxoethyl)amino]-5'-O-[
 (phenoxyacetyl)thymidylyl-(3'→5')-3'-O-[bis(4-methoxyphenyl)phenylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




OSC.G 21 THERE ARE 21 CAPLUS RECORDS THAT CITE THIS RECORD (21 CITINGS)

L4 ANSWER 59 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1981:462616 CAPLUS
 DN 95:62616
 OREF 95:10591a,10594a


TI Synthesis and properties of oligonucleotidyl -(Pm → N)- and -(Pm → O)-serines
 AU Liorancaite, L.; Bagdonas, A.
 CS Vilnius State Univ., Vilnius, USSR
 SO Aktual. Probl. Razvit. Nauchn. Issled. Molodykh Uch. Spets. Vil'nyus.
 Gosuniv. im. V. Kapsukasa, Mater. Konf. Molodykh Uch. Spets. Estestv.
 Khim. Fak. (1980), 35-6. Editor(s): Grigonis, I. Publisher: Vil'nyus.
 Gos. Univ. im. V. Kapsukasa, Vilnius, USSR.
 CODEN: 44ZNA8
 DT Conference
 LA Russian
 AB The title compds. EtO-Ser-(PM-°N)-d(TPT) (I) and
 EtO-Ser-(PM-°O)-d(TpT) were prepared from H-Ser-OEt and d(TpT). I is
 relatively stable in acid solution, but hydrolyzes in basic solution to give
 products indicating both P-N and P-O cleavage, the former presumably via
 β-elimination of the serine residue.
 IT 78396-63-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn and hydrolysis of)
 RN 78396-63-1 CAPLUS
 CN L-Serine, N-3'-thymidylyl-, 1-ethyl ester, P→5'-ester with
 thymidine (9CI) (CA INDEX NAME)



L4 ANSWER 60 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1978:580327 CAPLUS
 DN 89:180327
 OREF 89:28027a,28030a
 TI Phenomenon of intramolecular catalysis in oligonucleotidyl (Pm → N)-amino acids
 AU Leimontaite, R.; Liorancaite, L.; Juodaka, B.
 CS Vil'nyus. Gos. Univ., Vilnius, USSR
 SO Tezisy Dokl. - Resp. Konf. Molodykh Uch.-Khim., 2nd (1977), Volume 1, 157
 Publisher: Akad. Nauk Est. SSR, Inst. Khim., Tallinn, USSR.
 CODEN: 38RMAG
 DT Conference
 LA Russian
 AB Thymidylyl-(3' → 5)-thymidine(Pm → N)DL-phenylalanine Et
 ester (I) was prepared by the pyrophosphate method and saponified to give
 thymidylyl-(3' → 5)-thymidine(Pm → N)DL-phenylalanine (II).
 I was stable in alkaline and neutral solution and hydrolyzed in 2N HCl at
 50° to give thymidylylthymidine (III) and Phe-OEt. II was more
 reactive in acidic media and hydrolyzed to give III, phenylalanine,
 thymidine, thymidylic acid, and N-thymidylyl-DL-phenylalanine.
 IT 68058-22-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and hydrolysis of)
 RN 68058-22-0 CAPLUS
 CN Thymidine, P-deoxy-P-[[(2-ethoxy-2-oxo-1-
 (phenylmethyl)ethyl]amino]thymidylyl-(3'→5')- (9CI) (CA INDEX
 NAME)



L4 ANSWER 61 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1978:121671 CAPLUS
 DN 88:121671
 OREF 88:19113a,19116a
 TI Synthesis of nucleotidyl- and oligonucleotidyl ($P \rightarrow N$) lysines and their immobilization on Sepharose
 AU Juodka, B.; Liorancaite, I.; Leimontaite, R.; Malinauskas, A.; Kulys, J.; Sokolova, N. I.; Shabarova, Z. A.
 CS Vil'nyus. Gos. Univ., Vilnius, USSR
 SO Khimiya Prirodnykh Soedinenii (1977), (3), 435-6
 CODEN: KPSUAR; ISSN: 0023-1150
 DT Journal
 LA Russian
 AB R-DL-Lys(OR)-OR1 (R = 5'-adenylyl, 5'-thymidylyl, Q; R1 = H, Et) were prepared by pyrophosphate, dicyclohexylcarbodiimide, or mixed anhydride condensation reactions and immobilized by treatment with cyanogen bromide activated Sepharose 4B.
 IT 65718-47-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and immobilization on Sepharose)
 RN 65718-47-0 CAPLUS
 CN Thymidine, P-[(5-amino-1-(ethoxycarbonyl)pentyl)amino]-P-deoxythymidylyl-(3' \rightarrow 5')- (9CI) (CA INDEX NAME)




L4 ANSWER 62 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1974:449967 CAPLUS
 DN 81:49967
 OREF 81:7983a,7986a
 TI Oligonucleotidic compounds. XLVII. Synthesis of diribonucleoside phospho(P . far. N)amino acid derivatives
 AU Juodka, B. A.; Smrt, Jiri
 CS Cesk. Akad. Ved, Prague, Czech.
 SO Collection of Czechoslovak Chemical Communications (1974), 39(4), 963-8
 CODEN: CCCCAK; ISSN: 0010-0765
 DT Journal
 LA English
 AB 5'-O-Dimethoxytrityl-2'-O-tetrahydropyranyluridylyl-(3' \rightarrow 5')-2',-3'-O-ethoxymethyleneuridine-(P \rightarrow N)-cyclohexylamide and (P \rightarrow N)-glycine Et ester, and 5'-O-dimethoxytrityl-2'-O-acetyl-N6-acetyladenylyl-(3' \rightarrow 5')-2',3'-di-O-benzoyluridine-(P \rightarrow N)-DL-alanine tert-Bu ester were prepared from fully protected uridylyl-(3' \rightarrow 5')-uridine and adenylyl-(3' \rightarrow 5')-uridine with the use of bis(p-nitrophenyl) phosphochloridate.
 IT 53810-62-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 53810-62-1 CAPLUS
 CN Adenosine, 2',3'-di-O-benzoyl-P-deoxy-P-[2-(1,1-dimethylethyl)-1-methyl-2-oxoethyl]amino]-uridylyl-(5'→3')-N-acetyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-, 2'-acetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L4 ANSWER 63 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1971:471336 CAPLUS
 DN 75:71336
 OREF 75:11256h,11257a
 TI Optical rotatory dispersion and circular dichroism of mono- and oligonucleotide-amino acids (amides)
 AU Gromova, E. S.; Tyaglov, B. V.; Shabarova, Z. A.
 CS Lab. Bioorg. Chem., Moscow State Univ., Moscow, USSR
 SO Biochimica et Biophysica Acta, Nucleic Acids and Protein Synthesis (1971),
 240(1), 1-11
 CODEN: BBNPAS; ISSN: 0005-2787
 DT Journal
 LA English
 AB ORD and CD of 23 mono- and oligonucleotide amino acids were studied. ORD and CD of purine nucleotides with an aromatic amino acid or amine display a Cotton effect of opposite sign and greater amplitude than that of unsubstituted nucleotides.
 IT 33644-82-5
 RL: PRP (Properties)
 (optical properties of)
 RN 33644-82-5 CAPLUS
 CN Alanine, 3-phenyl-N-phosphono-, 1-methyl ester, DL-, 3'-ester with thymidine, 5'-ester with uridine (8CI) (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L4 ANSWER 64 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1967:55702 CAPLUS
 DN 66:55702
 OREF 66:10551a,10554a
 TI Synthesis of thymidylyl-(3' → 5')-uridyl-(P → N)-phenylalanine
 AU Sokolova, N. I.; Mel'nikova, V. I.; Shabarova, Z. A.; Prokof'ev, M. A.
 CS Univ., Moscow, USSR
 SO Vestnik Moskovskogo Universiteta, Seriya 2: Khimiya (1966), 21(5), 119-21
 CODEN: VMUKA5; ISSN: 0579-9384
 DT Journal
 LA Russian
 GI For diagram(s), see printed CA Issue.
 AB A solution of 150 mg. of 2',3'-diacetyluridine 5'-phosphate pyridine salt and 145 mg. of 5'-tritylthymidine in 3 ml. dry C5H5N with 306 mg. hexylcarbodiimide was evaporated after 3 days and the residue treated with hot 80% AcOH to cleave the trityl group. After saponification (pH 13, 25°, 30 min.) the product was purified by ion exchange (Amberlite IR-120, H form) and paper (7:1:22-propanol-concentrated NH4OH-H2O) chromatography to yield 70% thymidylyl-(3' → 5')-uridine (I), λ_{maximum} 265m μ (50% EtOH). The mixed anhydride formed in dry dioxane from 0.065 millimole I and 0.13 millimole diphenyl phosphorochloride was treated with 0.33 millimole Me phenylalaninate (II). The product was purified by paper chromatography as above to yield 50% thymidylyl-(3' → 5')-uridyl-(P → N)-phenylalanine methyl ester (III), λ_{maximum} 266 m μ . Hydrolysis of III in 0.1N HCl (1 hr., 70°) gave I and II.
 IT 14364-63-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 14364-63-7 CAPLUS
 CN Thymidine, 3'-ester with 3-phenyl-N-phosphonoalanine 1-methyl ester
 5'-ester with uridine (8CI) (CA INDEX NAME)



L4 ANSWER 65 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1966:68146 CAPLUS
 DN 64:68146
 OREF 64:12777g-h
 TI Preparation of dicyclopropylcarbinyl phosphorochloride and its use in phosphorylation reactions
 AU Schoffstall, A. M.; Tieckelmann, H.
 CS State Univ. of New York, Buffalo
 SO Tetrahedron (1966), 22(2), 399-406
 CODEN: TETRAB; ISSN: 0040-4020
 DT Journal
 LA English

OS CASREACT 64:68146

AB Dicyclopropylcarbonyl phosphorochloride was synthesized for use in phosphorylation reactions. This reagent and primary or secondary alcs. gave the corresponding esters. It reacted with primary and secondary hydroxyl functions of nucleosides to form nucleotide triesters. Dicyclopropylcarbonyl methyl phosphate was hydrolyzed by aqueous acid to monomenthyl phosphate. The nucleotide triesters gave free nucleotides in amts. reflecting their labilities in acid. Thus, uridine 5'-phosphate was produced in 53% overall yield from 2',3'-O-isopropylideneuridine, whereas thymidine 3'-phosphate was obtained in only 12% yield from 5'-O-tritylthymidine.


IT 6773-50-8

(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 6773-50-8 CAPLUS

CN Thymidine, 3',5'''-diester with 3-phenyl-N-phosphonoalanine methyl ester
(7CI, 8CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 66 OF 66 CAPLUS COPYRIGHT 2010 ACS on STN

AN 1966:68145 CAPLUS

DN 64:68145

OREF 64:12777d-g

TI Dinucleoside phospho-(PM → N)-amino acids

AU Vorob'ev, O. E.; Sokolova, N. I.; Mel'nikova, V. I.; Shabarova, Z. A.; Prokof'ev, M. A.

CS State Univ., Moscow

SO Doklady Akademii Nauk SSSR (1966), 166(1), 95-8

CODEN: DANKAS; ISSN: 0002-3264

DT Journal

LA Russian

GI For diagram(s), see printed CA Issue.

AB Treatment of thoroughly dried 2',5-di-O-acetyluridine 3'-phosphate pyridinium salt with 2',3'-O-isopropylideneuridine (2 moles) in pyridine with N,N'-dicyclohexylcarbodiimide 7 days gave after an aqueous treatment and electrophoretic purification at pH 7.5, 30% I (U = uridinyl group), isolated as the Et₃N salt, a colorless powder. This in Me₂NCHO with (PhO)₂POCl in the presence of Bu₃N 2 hrs., followed by phenylalanine Me ester overnight, gave after electrophoretic purification at pH 7.5, 10% II (U = uridinyl group), which in 20 hrs. at 37° in bicarbonate-carbonate buffer at pH 10.5 gave phenylalanine and uridyl-(3' → 5')-2',3'-O-isopropylideneuridine in nearly 100% yield. Similarly, thymidyl(3' → 5')-thymidine NH₄ salt, converted to trioctylamine salt, was treated with (PhO)₂POCl to yield 70% III (T = thymidyl group), as above. The uv spectra were reported. III was fairly stable in an alkaline solution

IT 6773-50-8

(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 6773-50-8 CAPLUS

CN Thymidine, 3',5'''-diester with 3-phenyl-N-phosphonoalanine methyl ester
(7CI, 8CI) (CA INDEX NAME)

Absolute stereochemistry.

